



MMWRTM

Morbidity and Mortality Weekly Report

Recommendations and Reports

November 22, 2002 / Vol. 51 / No. RR-18

U.S. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States

INSIDE: Continuing Education Examination

CENTERS FOR DISEASE CONTROL AND PREVENTION

SAFER • HEALTHIER • PEOPLETM

The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

Centers for Disease Control and Prevention. U.S. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1–Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States. *MMWR* 2002;51(No. RR-18):[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, M.D., M.P.H.
Director

David W. Fleming, M.D.
Deputy Director for Science and Public Health

Dixie E. Snider, Jr., M.D., M.P.H.
Associate Director for Science

Epidemiology Program Office

Stephen B. Thacker, M.D., M.Sc.
Director

Office of Scientific and Health Communications

John W. Ward, M.D.
Director
Editor, MMWR Series

Suzanne M. Hewitt, M.P.A.
Managing Editor

Lynne McIntyre, M.A.L.S.
Project Editor

Lynda G. Cupell
Visual Information Specialist

Quang M. Doan
Erica R. Shaver
Information Technology Specialists

CONTENTS

Introduction	1
Background	3
Considerations Regarding Use of Antiretroviral Drugs by HIV-1–infected Pregnant Women and Their Infants	3
Combination Antiretroviral Therapy and Pregnancy Outcome	3
Protease Inhibitor Therapy and Hyperglycemia	5
Mitochondrial Toxicity and Nucleoside Analog Drugs	5
Antiretroviral Pregnancy Registry	7
Update on PACTG 076 Results and Other Studies Relevant to ZDV Chemoprophylaxis for Perinatal HIV-1 Transmission	7
Preconception Counseling and Care for HIV-1–Infected Women of Childbearing Age	10
General Principles Regarding the Use of Antiretroviral Agents in Pregnancy	11
Recommendations for Antiretroviral Chemoprophylaxis to Reduce Perinatal HIV-1 Transmission	12
Clinical Situations and Recommendations for Use of Antiretroviral Prophylaxis	14
Antiretroviral Drug Resistance and Resistance Testing in Pregnancy	20
Perinatal HIV-1 Transmission and Mode of Delivery	22
Transmission and Mode of Delivery	22
Transmission, Viral Load, and Combination Antiretroviral Therapy	23
Maternal Risks by Mode of Delivery	24
Timing of Scheduled Cesarean Delivery	25
Intrapartum Management	25
Summary	25
Clinical Situations	26
Recommendations for Monitoring of Women and Their Infants	29
Clinical Research Needs	31
References	32

The preparer of this report has no conflict of interest with the manufacturers or products discussed herein.

U.S. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1–Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States*

Prepared by
Lynne M. Mofenson, M.D.
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
National Institutes of Health

Summary

These recommendations update the February 4, 2002, guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission. This report provides health-care providers with information for discussion with HIV-1–infected pregnant women to enable such women to make an informed decision regarding the use of antiretroviral drugs during pregnancy and use of elective cesarean delivery to reduce perinatal HIV-1 transmission. Various circumstances that commonly occur in clinical practice are presented, and the factors influencing treatment considerations are highlighted in this report. The Perinatal HIV Guidelines Working Group recognizes that strategies to prevent perinatal transmission and concepts related to management of HIV disease in pregnant women are rapidly evolving and will continually review new data and provide regular updates to the guidelines. The most recent information is available from the HIV/AIDS Treatment Information Service (available at <http://www.hivatis.org>).

In February 1994, the results of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 documented that ZDV chemoprophylaxis could reduce perinatal HIV-1 transmission by nearly 70%. Epidemiologic data have since confirmed the efficacy of ZDV for reduction of perinatal transmission and have extended this efficacy to children of women with advanced disease, low CD4⁺ T-lymphocyte counts, and prior ZDV therapy. Additionally, substantial advances have been made in the understanding of the pathogenesis of HIV-1 infection and in the treatment and monitoring of persons with HIV-1 disease. These advances have resulted in changes in standard antiretroviral therapy for HIV-1–infected adults. More aggressive combination drug regimens that maximally suppress viral replication are now recommended. Although considerations associated with pregnancy may affect decisions regarding timing and choice of therapy, pregnancy is not a reason to defer standard therapy. Use of antiretroviral drugs in pregnancy requires unique considerations, including the possible need to alter dosage as a result of physiologic changes associated with pregnancy, the potential for adverse short- or long-term effects on the fetus and newborn, and the effectiveness of the drugs in reducing the risk for perinatal transmission. Data to address many of these considerations are not yet available. Therefore, offering antiretroviral therapy to HIV-1–infected women during pregnancy, whether primarily for HIV-1 infection, for reduction of perinatal transmission, or for both purposes, should be accompanied by a discussion of the known and unknown short- and long-term benefits and risks of such therapy to infected women and their infants. Standard antiretroviral therapy should be discussed with and offered to HIV-1–infected pregnant women. Additionally, to prevent perinatal transmission, ZDV chemoprophylaxis should be incorporated into the antiretroviral regimen.

Introduction

In February 1994, the Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 demonstrated that a three-part

The material in this report originated in the National Center for HIV, STD, and TB Prevention, Harold W. Jaffe, M.D., Director; Division of HIV/AIDS Prevention–Surveillance and Epidemiology, Robert S. Janssen, M.D., Director.

regimen of zidovudine (ZDV) could reduce the risk for mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by nearly 70% (1). The regimen includes oral ZDV initiated at 14–34 weeks' gestation and continued throughout pregnancy, followed by intravenous ZDV during labor and oral administration of ZDV to the infant for 6 weeks after delivery (Table 1). In August 1994, a U.S. Public Health Service (USPHS) task force issued recommendations for the use of ZDV for reduction of perinatal HIV-1 transmission

*Information included in these guidelines may not represent approval by the Food and Drug Administration (FDA) or approved labeling for the particular product or indications in question. Specifically, the terms "safe" and "effective" may not be synonymous with the FDA-defined legal standards for product approval.

TABLE 1. Pediatric AIDS Clinical Trials Group (PACTG) 076 zidovudine (ZDV) regimen

Time of ZDV administration	Regimen
Antepartum	Oral administration of 100 mg ZDV five times daily,* initiated at 14–34 weeks' gestation and continued throughout the pregnancy.
Intrapartum	During labor, intravenous administration of ZDV in a 1-hour initial dose of 2 mg/kg body weight, followed by a continuous infusion of 1 mg/kg body weight per hour until delivery.
Postpartum	Oral administration of ZDV to the newborn (ZDV syrup at 2 mg/kg body weight/dose every 6 hours) for the first 6 weeks of life, beginning at 8–12 hours after birth.†

* Oral ZDV, administered as 200 mg three times daily or 300 mg twice daily, is used in general clinical practice and is an acceptable alternative regimen to 100 mg orally five times daily.

† Intravenous dosage for infants who cannot tolerate oral intake is 1.5 mg/kg body weight intravenously every 6 hours.

(2), and in July 1995, USPHS issued recommendations for universal prenatal HIV-1 counseling and HIV-1 testing with consent for all pregnant women in the United States (3). Since the publication of the results of PACTG 076, epidemiologic studies in the United States and France have demonstrated dramatic decreases in perinatal transmission with incorporation of the PACTG 076 ZDV regimen into general clinical practice (4–9).

Since 1994, advances have been made in the understanding of the pathogenesis of HIV-1 infection and in the treatment and monitoring of HIV-1 disease. The rapidity and magnitude of viral turnover during all stages of HIV-1 infection are greater than previously recognized; plasma virions are estimated to have a mean half-life of only 6 hours (10). Thus, current therapeutic interventions focus on early initiation of aggressive combination antiretroviral regimens to maximally suppress viral replication, preserve immune function, and reduce the development of resistance (11). New, potent antiretroviral drugs that inhibit the protease enzyme of HIV-1 are now available. When a protease inhibitor is used in combination with nucleoside analog reverse transcriptase inhibitors, plasma HIV-1 RNA levels can be reduced for prolonged periods to levels that are undetectable by current assays. Improved clinical outcome and survival have been observed among adults receiving such regimens (12,13). Additionally, viral load can now be more directly quantified through assays that measure HIV-1 RNA copy number; these assays have provided powerful new tools to assess disease stage, risk for progression, and the effects of therapy. These advances have led to substantial

changes in the standard of treatment and monitoring for HIV-1-infected adults in the United States (14).

Advances also have been made in the understanding of the pathogenesis of perinatal HIV-1 transmission. Most perinatal transmission likely occurs close to the time of or during childbirth (15). Additional data that demonstrate the short-term safety of the ZDV regimen are now available as a result of follow-up of infants and women enrolled in PACTG 076; however, data from studies of animals concerning the potential for transplacental carcinogenicity of ZDV affirm the need for long-term follow-up of children with antiretroviral exposure in utero (16).

These advances have implications for maternal and fetal health. Health-care providers considering the use of antiretroviral agents for HIV-1-infected women during pregnancy must take into account two separate but related issues: 1) antiretroviral treatment of maternal HIV-1 infection, and 2) antiretroviral chemoprophylaxis to reduce the risk for perinatal HIV-1 transmission. The benefits of antiretroviral therapy for a pregnant woman must be weighed against the risk of adverse events to the woman, fetus, and newborn. Although ZDV chemoprophylaxis alone has substantially reduced the risk for perinatal transmission, antiretroviral monotherapy is now considered suboptimal for treatment of HIV-1 infection, and combination drug regimens are considered the standard of care for therapy (14).

This report reviews the special considerations regarding use of antiretroviral drugs for pregnant women, updates the results of PACTG 076 and related clinical trials and epidemiologic studies, discusses use of HIV-1 RNA and antiretroviral drug resistance assays during pregnancy, provides updated recommendations on antiretroviral chemoprophylaxis for reducing perinatal transmission, and provides recommendations related to use of elective cesarean delivery as an intervention to reduce perinatal transmission.

These recommendations have been developed for use in the United States. Although perinatal HIV-1 transmission occurs worldwide, alternative strategies may be appropriate in other countries. Policies and practices in other countries regarding the use of antiretroviral drugs for reduction of perinatal HIV-1 transmission may differ from the recommendations in this report and will depend on local considerations, including availability and cost of ZDV, access by pregnant women to facilities for safe intravenous infusions during labor, and alternative interventions being evaluated in that area.

Background

Considerations Regarding Use of Antiretroviral Drugs by HIV-1–infected Pregnant Women and Their Infants

Treatment recommendations for pregnant women infected with HIV-1 have been based on the belief that therapies of known benefit to women should not be withheld during pregnancy unless there are known adverse effects on the mother, fetus, or infant and unless these adverse effects outweigh the benefit to the woman (17). Combination antiretroviral therapy, usually consisting of two nucleoside analog reverse transcriptase inhibitors and a protease inhibitor, is the recommended standard treatment for HIV-1–infected adults who are not pregnant (14). Pregnancy should not preclude the use of optimal therapeutic regimens. However, recommendations regarding the choice of antiretroviral drugs for treatment of infected pregnant women are subject to unique considerations. These include possible changes in dosing requirements resulting from physiologic changes associated with pregnancy, potential effects of antiretroviral drugs on the pregnant woman, and the potential short- and long-term effects of the antiretroviral drug on the fetus and newborn, which may not be known for certain antiretroviral drugs.

The decision to use any antiretroviral drug during pregnancy should be made by the woman after discussing with her health-care provider the known and unknown benefits and risks to her and her fetus.

Physiologic changes that occur during pregnancy may affect the kinetics of drug absorption, distribution, biotransformation, and elimination, thereby also affecting requirements for drug dosing and potentially altering the susceptibility of the pregnant woman to drug toxicity. During pregnancy, gastrointestinal transit time becomes prolonged; body water and fat increase throughout gestation and are accompanied by increases in cardiac output, ventilation, and liver and renal blood flow; plasma protein concentrations decrease; renal sodium reabsorption increases; and changes occur in metabolic enzyme pathways in the liver. Placental transport of drugs, compartmentalization of drugs in the embryo/fetus and placenta, biotransformation of drugs by the fetus and placenta, and elimination of drugs by the fetus also can affect drug pharmacokinetics in the pregnant woman. Additional considerations regarding drug use in pregnancy are the effects of the drug on the fetus and newborn, including the potential for teratogenicity, mutagenicity, or carcinogenicity, and the pharmacokinetics and toxicity of transplacentally transferred drugs.

The potential harm to the fetus from maternal ingestion of a specific drug depends not only on the drug itself, but on the dose ingested, the gestational age of the fetus at exposure, the duration of exposure, the interaction with other agents to which the fetus is exposed, and, to an unknown extent, the genetic makeup of the mother and fetus.

Information regarding the safety of drugs in pregnancy is derived from animal toxicity data, anecdotal experience, registry data, and clinical trials. Data are limited for antiretroviral drugs, particularly when used in combination therapy. Drug choice should be individualized and must be based on discussion with the woman and available data from preclinical and clinical testing of the individual drugs.

Preclinical data include results of in vitro and animal in vivo screening tests for carcinogenicity, clastogenicity/mutagenicity, and reproductive and teratogenic effects. However, the predictive value of such tests for adverse effects in humans is unknown. For example, of approximately 1,200 known animal teratogens, only about 30 are known to be teratogenic in humans (18). In addition to antiretroviral agents, certain drugs commonly used to treat HIV-1–related illnesses demonstrate positive findings on one or more of these screening tests. For example, acyclovir is positive in some in vitro carcinogenicity and clastogenicity assays and is associated with fetal abnormalities in rats; however, data collected on the basis of human experience from the Acyclovir in Pregnancy Registry have indicated no increased risk for birth defects in infants with in utero exposure to acyclovir (19). Limited data exist regarding placental passage and long-term animal carcinogenicity for the FDA-approved antiretroviral drugs (Table 2) (20).

Combination Antiretroviral Therapy and Pregnancy Outcome

Data are conflicting as to whether receipt of combination antiretroviral therapy during pregnancy is associated with adverse pregnancy outcomes such as preterm delivery. A retrospective Swiss report evaluated the pregnancy outcome of 37 HIV-1–infected pregnant women treated with combination therapy; all received two reverse transcriptase inhibitors and 16 received one or two protease inhibitors (21). Almost 80% of women experienced one or more typical adverse effects of the drugs, such as anemia, nausea/vomiting, aminotransferase elevation, or hyperglycemia. A possible association of combination antiretroviral therapy with preterm births was noted; 10 of 30 babies were born prematurely. The preterm birth rate did not differ between women receiving

TABLE 2. Preclinical and clinical data relevant to the use of antiretroviral agents in pregnancy

Antiretroviral drug	FDA pregnancy category*	Placental passage (newborn:mother drug ratio)	Long-term animal carcinogenicity studies	Animal teratogen studies
Nucleoside and nucleotide analog reverse transcriptase inhibitors				
Zidovudine (Retrovir®, AZT, ZDV)	C	Yes (human) (0.85)	Positive (rodent, noninvasive vaginal epithelial tumors)	Positive (rodent, near lethal dose)
Zalcitabine (HIVID®, ddC)	C	Yes (rhesus monkey) (0.30–0.50)	Positive (rodent, thymic lymphomas)	Positive (rodent, hydrocephalus at high dose)
Didanosine (Videx®, ddl)	B	Yes (human) (0.5)	Negative (no tumors, lifetime rodent study)	Negative
Stavudine (Zerit®, d4T)	C	Yes (rhesus monkey) (0.76)	Not completed	Negative (but sternal bone calcium decreases in rodents)
Lamivudine (EpiVir®, 3TC)	C	Yes (human) (~1.0)	Negative (no tumors, lifetime rodent study)	Negative
Abacavir (Ziagen®, ABC)	C	Yes (rats)	Not completed	Positive (rodent, anasarca and skeletal malformations at 1000 mg/kg (35x human exposure) during organogenesis; not seen in rabbits)
Tenofovir DF (Viread®)	B	Yes (rat and monkey)	Not completed	Negative (osteomalacia when given to juvenile animals at high doses)
Non-nucleoside reverse transcriptase inhibitors				
Nevirapine (Viramune®)	C	Yes (human) [~1.0]	Not completed	Negative
Delavirdine (Rescriptor®)	C	Unknown	Not completed	Positive (rodent, ventricular septal defect)
Efavirenz (Sustiva®)	C	Yes (cynomologus monkey, rat, rabbit) [~1.0]	Not completed	Positive (cynomologus monkey, anencephaly, anophthalmia, microphthalmia)
Protease inhibitors				
Indinavir (Crixivan®)	C	Minimal (human)	Not completed	Negative (but extra ribs in rodents)
Ritonavir (Norvir®)	B	Minimal (human)	Positive (rodent, liver adenomas and carcinomas in male mice)	Negative (but cryptorchidism in rodents)
Saquinavir (Fortovase®–soft gel) (Invirase®–hard gel)	B	Minimal (human)	Not completed	Negative
Nelfinavir (Viracept®)	B	Minimal (human)	Not completed	Negative
Amprenavir (Agenerase®)	C	Unknown	Not completed	Negative (but deficient ossification and thymic elongation in rats and rabbits)
Lopinavir-Ritonavir (Kaletra®)	C	Unknown	Not completed	Negative (but delayed skeletal ossification and increase in skeletal variations in rats at maternally toxic doses)

*FDA pregnancy categories:

- A Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no evidence of risk during later trimesters).
 B Animal reproduction studies fail to demonstrate a risk to the fetus, and adequate and well-controlled studies of pregnant women have not been conducted.
 C Safety in human pregnancy has not been determined, animal studies are either positive for fetal risk or have not been conducted, and the drug should not be used unless the potential benefit outweighs the potential risk to the fetus.
 D Positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experiences, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.
 X Studies with animals or reports of adverse reactions have indicated that the risk associated with the use of the drug for pregnant women clearly outweighs any possible benefit.

combination therapy with or without protease inhibitors. The contribution of maternal HIV-1 disease stage and other covariates that might be associated with a risk for prematurity was not assessed.

The European Collaborative Study and the Swiss Mother + Child HIV-1 Cohort Study investigated the effects of combination retroviral therapy in a population of 3,920 mother-child pairs. Adjusting for CD4⁺ T-lymphocyte count (CD4⁺ count) and intravenous drug use, they found a 2.6-fold (95% confidence interval [CI] = 1.4–4.8) increased odds of preterm delivery for infants exposed to combination therapy with or without protease inhibitors compared with no treatment; women receiving combination therapy that had been initiated before their pregnancy were twice as likely to deliver prematurely as those starting therapy during the third trimester (22). However, combination therapy was received by only 323 (8%) women studied. Exposure to monotherapy was not associated with prematurity.

In contrast, in an observational study of pregnant women with HIV-1 infection in the United States (PACTG 367) in which 1,150 (78%) of 1,472 women received combination therapy, no association was found between receipt of combination therapy and preterm birth (23). The highest rate of preterm delivery was among women who had not received any antiretroviral therapy, which is consistent with several other reports demonstrating elevated preterm birth rates among untreated women with HIV-1 infection (24–26). In a French open-label study of 445 HIV-1–infected women receiving ZDV who had lamivudine (3TC) added to their therapy at 32 weeks' gestation, the rate of preterm delivery was 6%, similar to the 9% rate in a historical control group of women receiving only ZDV (27). Additionally, in a large meta-analysis of seven clinical studies that included 2,123 HIV-infected pregnant women who delivered infants during 1990–1998 and had received antenatal antiretroviral therapy and 1,143 women who did not receive antenatal antiretroviral therapy, use of multiple antiretroviral drugs as compared with no treatment or treatment with one drug was not associated with increased rates of preterm labor, low birth weight, low Apgar scores, or stillbirth (28).

Until more information is known, HIV-1–infected pregnant women who are receiving combination therapy for their HIV-1 infection should continue their provider-recommended regimen. They should receive careful, regular monitoring for pregnancy complications and for potential toxicities.

Protease Inhibitor Therapy and Hyperglycemia

Hyperglycemia, new-onset diabetes mellitus, exacerbation of existing diabetes mellitus, and diabetic ketoacidosis have been reported with receipt of protease inhibitor antiretroviral drugs by HIV-1–infected patients (29–32). In addition, pregnancy is itself a risk factor for hyperglycemia; it is unknown if the use of protease inhibitors will increase the risk for pregnancy-associated hyperglycemia. Clinicians caring for HIV-1–infected pregnant women who are receiving protease inhibitor therapy should be aware of the risk of this complication and closely monitor glucose levels. Symptoms of hyperglycemia should be discussed with pregnant women who are receiving protease inhibitors.

Mitochondrial Toxicity and Nucleoside Analog Drugs

Nucleoside analog drugs are known to induce mitochondrial dysfunction because the drugs have varying affinity for mitochondrial gamma DNA polymerase. This affinity can interfere with mitochondrial replication, resulting in mitochondrial DNA depletion and dysfunction (33). The relative potency of the nucleosides in inhibiting mitochondrial gamma DNA polymerase in vitro is highest for zalcitabine (ddC), followed by didanosine (ddI), stavudine (d4T), 3TC, ZDV and abacavir (ABC) (34). Toxicity related to mitochondrial dysfunction has been reported to occur in infected patients receiving long-term treatment with nucleoside analogs and generally has resolved with discontinuation of the drug or drugs; a possible genetic susceptibility to these toxicities has been suggested (33). These toxicities may be of particular concern for pregnant women and infants with in utero exposure to nucleoside analog drugs.

During Pregnancy

Clinical disorders linked to mitochondrial toxicity include neuropathy, myopathy, cardiomyopathy, pancreatitis, hepatic steatosis, and lactic acidosis. Among these disorders, symptomatic lactic acidosis and hepatic steatosis may have a female preponderance (35). These syndromes have similarities to rare but life-threatening syndromes that occur during pregnancy, most often during the third trimester: acute fatty liver, and the combination of hemolysis, elevated liver enzymes and low platelets (the HELLP syndrome). Several investigators have

correlated these pregnancy-related disorders with a recessively inherited mitochondrial abnormality in the fetus/infant that results in an inability to oxidize fatty acids (36–38). Since the mother would be a heterozygotic carrier of the abnormal gene, the risk for liver toxicity might be increased during pregnancy because the mother would be unable to properly oxidize both maternal and accumulating fetal fatty acids (39). Additionally, animal studies have demonstrated that in late gestation, pregnant mice have significant reductions (25%–50%) in mitochondrial fatty acid oxidation and that exogenously administered estradiol and progesterone can reproduce these effects (40,41); whether this can be translated to humans is unknown. However, these data suggest that a disorder of mitochondrial fatty acid oxidation in the mother or her fetus during late pregnancy may play a role in the development of acute fatty liver of pregnancy and HELLP syndrome and possibly contribute to susceptibility to antiretroviral-associated mitochondrial toxicity.

Lactic acidosis with microvacuolar hepatic steatosis is a toxicity related to nucleoside analog drugs that is thought to be related to mitochondrial toxicity; it has been reported to occur in infected persons treated with nucleoside analog drugs for long periods (>6 months). Initially, most cases were associated with ZDV, but later other nucleoside analog drugs, particularly d4T, have been associated with the syndrome. In a report from the FDA Spontaneous Adverse Event Program of 106 patients with this syndrome (60 receiving combination and 46 receiving single nucleoside analog therapy), typical initial symptoms included 1 to 6 weeks of nausea, vomiting, abdominal pain, dyspnea, and weakness (35). Metabolic acidosis with elevated serum lactate and elevated hepatic enzymes was common. Patients described in that report were predominantly female and overweight. The incidence of this syndrome may be increasing, possibly as a result of increased use of combination nucleoside analog therapy or increased recognition of the syndrome. In a cohort of infected patients receiving nucleoside analog therapy followed at Johns Hopkins University during 1989–1994, the incidence of the hepatic steatosis syndrome was 0.13% per year (42). However, in a report from a cohort of 964 HIV-1-infected persons followed in France for 2 years during 1997–1999, the incidence of symptomatic hyperlactatemia was 0.8% per year for all patients and 1.2% for patients receiving a regimen including d4T (43).

The frequency of this syndrome in pregnant HIV-1-infected women receiving nucleoside analog treatment is unknown. In 1999, Italian researchers reported a case of severe lactic acidosis in an infected pregnant woman who was receiving d4T-3TC at the time of conception and throughout pregnancy and who experienced symptoms and fetal death at 38 weeks'

gestation (44). Bristol-Myers Squibb has reported three maternal deaths due to lactic acidosis, two with and one without accompanying pancreatitis, among women who were either pregnant or postpartum and whose antepartum therapy during pregnancy included d4T and ddI in combination with other antiretroviral agents (either a protease inhibitor or nevirapine) (45). All women were receiving treatment with these agents at the time of conception and continued for the duration of pregnancy; all presented late in gestation with symptomatic disease that progressed to death in the immediate postpartum period. Two cases were also associated with fetal death.

It is unclear if pregnancy augments the incidence of the lactic acidosis/hepatic steatosis syndrome that has been reported for nonpregnant persons receiving nucleoside analog treatment. However, because pregnancy itself can mimic some of the early symptoms of the lactic acidosis/hepatic steatosis syndrome or be associated with other disorders of liver metabolism, these cases emphasize the need for physicians caring for HIV-1-infected pregnant women receiving nucleoside analog drugs to be alert for early signs of this syndrome. Pregnant women receiving nucleoside analog drugs should have hepatic enzymes and electrolytes assessed more frequently during the last trimester of pregnancy, and any new symptoms should be evaluated thoroughly. Additionally, because of the reports of several cases of maternal mortality secondary to lactic acidosis with prolonged use of the combination of d4T and ddI by HIV-1-infected pregnant women, clinicians should prescribe this antiretroviral combination during pregnancy with caution and generally only when other nucleoside analog drug combinations have failed or have caused unacceptable toxicity or side effects.

In Utero Exposure

A study conducted in France reported that in a cohort of 1,754 uninfected infants born to HIV-1-infected women who received antiretroviral drugs during pregnancy, eight infants with in utero or neonatal exposure to either ZDV-3TC (four infants) or ZDV alone (four infants) developed indications of mitochondrial dysfunction after the first few months of life (46). Two of these infants (both of whom had been exposed to ZDV-3TC) contracted severe neurologic disease and died, three had mild to moderate symptoms, and three had no symptoms but had transient laboratory abnormalities. An association between these findings and in utero exposure to antiretroviral drugs has not been definitively established.

In infants followed through age 18 months in PACTG 076, the occurrence of neurologic events was rare; seizures occurred in one child exposed to ZDV and two exposed to placebo,

and one child in each group had reported spasticity. Mortality at 18 months was 1.4% among infants given ZDV compared with 3.5% among those given placebo (47). The Perinatal Safety Review Working Group performed a retrospective review of deaths occurring among children born to HIV-1-infected women and followed during 1986–1999 in five large prospective U.S. perinatal cohorts. No deaths similar to those reported from France or with clinical findings attributable to mitochondrial dysfunction were identified in a database of >16,000 uninfected children born to HIV-1-infected women with and without antiretroviral drug exposure (48). However, most of the infants with antiretroviral exposure had been exposed to ZDV alone and only a relatively small proportion (approximately 6%) had been exposed to ZDV-3TC. In an African perinatal trial (PETRA) that compared three regimens of ZDV-3TC (during pregnancy starting at 36 weeks' gestation, during labor, and through 1 week postpartum; during labor and postpartum; and during labor only) with placebo for prevention of transmission, data have been reviewed relating to neurologic adverse events among 1,798 children who participated. No increased risk of neurologic events was observed among children treated with ZDV-3TC compared with placebo, regardless of the intensity of treatment (49). Finally, in a study of 382 uninfected infants born to HIV-1-infected women, echocardiograms were prospectively performed every 4 to 6 months during the first 5 years of life; 9% of infants had been exposed to ZDV prenatally (50). No significant differences in ventricular function were observed between infants exposed and not exposed to ZDV.

Even if the association of mitochondrial dysfunction and in utero antiretroviral exposures is demonstrated, the development of severe or fatal mitochondrial disease in these infants appears to be extremely rare and should be compared against the clear benefit of ZDV in reducing transmission of a fatal infection by nearly 70% (51). These results emphasize the importance of the existing Public Health Service recommendation for long-term follow-up for any child with in utero exposure to antiretroviral drugs.

Antiretroviral Pregnancy Registry

Health-care providers who are treating HIV-1-infected pregnant women and their newborns are strongly advised to report instances of prenatal exposure to antiretroviral drugs (either alone or in combination) to the Antiretroviral Pregnancy Registry. This registry is an epidemiologic project to collect observational, nonexperimental data regarding antiretroviral exposure during pregnancy for the purpose of assessing the potential teratogenicity of these drugs. Registry

data will be used to supplement animal toxicology studies and assist clinicians in weighing the potential risks and benefits of treatment for individual patients. The Antiretroviral Pregnancy Registry is a collaborative project of pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners. The registry does not use patient names, and registry staff obtain birth outcome follow-up information from the reporting physician. Referrals should be directed to

Antiretroviral Pregnancy Registry

Research Park

1011 Ashes Drive

Wilmington, NC 28405

Telephone: 800-258-4263

Fax: 800-800-1052

Available at <http://www.apregistry.com>

Update on PACTG 076 Results and Other Studies Relevant to ZDV Chemoprophylaxis for Perinatal HIV-1 Transmission

In 1996, final results were reported for all 419 infants enrolled in PACTG 076. The results concur with those initially reported in 1994; the Kaplan-Meier estimated HIV-1 transmission rate for infants who received placebo was 22.6%, compared with 7.6% for those who received ZDV, a 66% reduction in risk for transmission (52).

The mechanism by which ZDV reduced transmission in PACTG 076 participants has not been fully defined. The effect of ZDV on maternal HIV-1 RNA does not fully account for the observed efficacy of ZDV in reducing transmission. Preexposure prophylaxis of the fetus or infant may offer substantial protection. If so, transplacental passage of antiretroviral drugs would be crucial for prevention of transmission. Additionally, in placental perfusion studies, ZDV has been metabolized into the active triphosphate within the placenta (53,54), which could provide additional protection against in utero transmission. This phenomenon may be unique to ZDV because metabolism to the active triphosphate form within the placenta has not been observed in the other nucleoside analogs that have been evaluated (i.e., ddI and ddC) (55,56).

In PACTG 076, similar rates of congenital abnormalities occurred among infants with and without in utero ZDV exposure. Data from the Antiretroviral Pregnancy Registry also have demonstrated no increased risk for congenital abnormalities among infants born to women who receive ZDV antenatally compared with the general population (57). Among

uninfected infants from PACTG 076 followed from birth to a median age of 4.2 years (range 3.2–5.6 years), no differences were noted in growth, neurodevelopment, or immunologic status between infants born to mothers who received ZDV compared with those born to mothers who received placebo (58). No malignancies have been observed in short-term (i.e., up to age 6 years) follow-up of >727 infants from PACTG 076 or from a prospective cohort study involving infants with in utero ZDV exposure (59). However, follow-up is too limited to provide a definitive assessment of carcinogenic risk with human exposure. Long-term monitoring continues to be recommended for all infants who have received in utero ZDV exposure or in utero exposure to any of the antiretroviral drugs.

The efficacy of ZDV chemoprophylaxis for reducing HIV-1 transmission among populations of infected women with characteristics unlike those of the PACTG 076 population has been evaluated in another perinatal protocol (PACTG 185) and in prospective cohort studies. PACTG 185 enrolled pregnant women with advanced HIV-1 disease and low CD4⁺ counts who were receiving antiretroviral therapy; 24% had received ZDV before the current pregnancy (60). All women and infants received the three-part ZDV regimen combined with either infusions of hyperimmune HIV-1 immunoglobulin (HIVIG) containing high levels of antibodies to HIV-1 or standard intravenous immunoglobulin (IVIG) without HIV-1 antibodies. Because advanced maternal HIV-1 disease has been associated with increased risk for perinatal transmission, the transmission rate in the control group was hypothesized to be 11%–15% despite the administration of ZDV. At the first interim analysis, the transmission rate for the combined group was only 4.8% and did not substantially differ by whether the women received HIVIG or IVIG or by duration of ZDV use (60). The results of this trial confirm the efficacy of ZDV observed in PACTG 076 and extend this efficacy to women with advanced disease, low CD4⁺ count, and prior ZDV therapy. Rates of perinatal transmission have been documented to be as low as 3%–4% among women with HIV-1 infection who receive all three components of the ZDV regimen, including women with advanced HIV-1 disease (6,60).

At least two studies suggest that antenatal use of combination antiretroviral regimens might further reduce transmission. In an open-label, nonrandomized study of 445 women with HIV-1 infection in France, 3TC was added at 32 weeks' gestation to standard ZDV prophylaxis; 3TC was also given to the infant for 6 weeks in addition to ZDV (27). The transmission rate in the ZDV-3TC group was 1.6% (95% CI = 0.7%–3.3%); in comparison, the transmission rate in a historical control group of women receiving only ZDV was 6.8%

(95% CI = 5.1%–8.7%). In a longitudinal epidemiologic study conducted in the United States since 1990, transmission was observed in 20% of women with HIV-1 infection who received no antiretroviral treatment during pregnancy, 10.4% who received ZDV alone, 3.8% who received combination therapy without protease inhibitors, and 1.2% who received combination therapy with protease inhibitors (61).

International Antiretroviral Prophylaxis Clinical Trials

In a trial evaluating short-course antenatal/intrapartum ZDV prophylaxis and perinatal transmission among non-breastfeeding women in Thailand, administration of ZDV 300 mg twice daily for 4 weeks antenatally and 300 mg every 3 hours orally during labor was shown to reduce perinatal transmission by approximately 50% compared with placebo (62). The transmission rate was 19% in the placebo group versus 9% in the ZDV group. A second, four-arm factorial design trial in Thailand compared administration of ZDV antenatally starting at 28 or 36 weeks' gestation, orally intrapartum, and to the neonate for 3 days or 6 weeks. At an interim analysis, the transmission rate in the arm receiving ZDV antenatally starting at 36 weeks and postnatally for 3 days to the infant was 10%, which was significantly higher than for the long-term arm (antenatal starting at 28 weeks and infant administration for 6 weeks) (63). The transmission rate in the short-short arm of this study was similar to the 9% observed with short antenatal/intrapartum ZDV in the first Thai study. The rate of in utero transmission was higher among women in the short antenatal arms compared with those receiving longer antenatal therapy, suggesting that longer treatment of the infant cannot substitute for longer treatment of the mother.

A third trial in Africa (PETRA trial) among breastfeeding HIV-1-infected women has shown that a combination regimen of ZDV and 3TC administered starting at 36 weeks' gestation, orally intrapartum, and for 1 week postpartum to the woman and infant reduced transmission at age 6 weeks by approximately 50% compared with placebo (64). The transmission rate at age 6 weeks was 15% in the placebo group versus 6% with the three-part ZDV-3TC regimen. This efficacy is similar to the efficacy observed in the Thailand study of antepartum/intrapartum short-course ZDV in non-breastfeeding women (62).

Investigators have identified two possible intrapartum/postpartum regimens (either ZDV-3TC or nevirapine) that could provide an effective intrapartum/postpartum intervention for women for whom the diagnosis of HIV-1 is not made until near to or during labor. The PETRA African ZDV-3TC trial among breastfeeding HIV-1-infected women also

demonstrated that an intrapartum/postpartum regimen, started during labor and continued for 1 week postpartum in the woman and infant, reduced transmission at age 6 weeks from 15% in the placebo group to 9% in the group receiving the two-part ZDV-3TC regimen, a reduction of 40% (64). In this trial, oral ZDV-3TC administered solely during the intrapartum period was not effective in lowering transmission. Another study in Uganda (HIVNET 012), again in a breastfeeding population, demonstrated that a single 200-mg oral dose of nevirapine given to the mother at onset of labor combined with a single 2-mg/kg oral dose given to her infant at age 48–72 hours reduced transmission by nearly 50% compared with a very short regimen of ZDV given orally during labor and to the infant for 1 week (65). Transmission at age 6 weeks was 12% in the nevirapine group compared with 21% in the ZDV group. A subsequent trial in South Africa demonstrated similar transmission rates with a modified HIVNET 012 nevirapine regimen (nevirapine given to the woman as a single dose during labor with a second dose at 48 hours postpartum, and a single dose to the infant at age 48 hours) compared with the PETRA regimen of oral ZDV-3TC during labor and for 1 week after delivery to the mother and infant (66). Transmission rates at age 8 weeks were 13.3% in the nevirapine arm and 10.9% in the ZDV-3TC arm.

Two clinical trials have suggested that the addition of the HIVNET 012 single-dose nevirapine regimen to short-course ZDV may provide increased efficacy in reducing perinatal transmission. A study of nonbreastfeeding women in Thailand compared a short-course ZDV regimen (starting at 28 weeks' gestation, given orally intrapartum, and for 1 week to the infant) with two combination regimens: short-course ZDV plus single-dose intrapartum/neonatal nevirapine, and short-course ZDV plus intrapartum maternal nevirapine only. In the short-course ZDV-only arm, enrollment was discontinued by the Data and Safety Monitoring Board at the first interim analysis because transmission was significantly higher among those receiving ZDV alone compared with those receiving the intrapartum/neonatal nevirapine combination regimen (67). The study is continuing to enroll to allow comparison of the two combination arms. A second open-label study in Cote d'Ivoire reported a 7.1% transmission rate at age 4 weeks with administration of short-course ZDV (starting at 36 weeks, given orally intrapartum, and for 1 week to the infant) combined with single-dose intrapartum/neonatal nevirapine. This was lower than for a nonconcurrent historical control group receiving ZDV alone (68).

In contrast to these studies, which evaluated combining single-dose nevirapine with short-course ZDV, a study in the United States, Europe, Brazil, and the Bahamas (PACTG 316)

evaluated whether the addition of the HIVNET 012 single-dose nevirapine regimen to standard antiretroviral therapy (at minimum the 3-part full ZDV regimen) would provide additional benefits in lowering transmission. In this study, 1,506 pregnant women with HIV-1 infection who were receiving antiretroviral therapy (77% were receiving combination antiretroviral regimens) were randomized to receive a single dose of nevirapine or nevirapine placebo at onset of labor, and their infants received a single dose (according to the maternal randomization) at age 48 hours. Transmission was not significantly different between groups, occurring in 1.6% of women in the placebo group and 1.4% among women in the nevirapine group (69).

Certain data indicate that postexposure antiretroviral prophylaxis of infants whose mothers did not receive antepartum or intrapartum antiretroviral drugs might provide some protection against transmission. Although data from some epidemiologic studies do not support efficacy of postnatal ZDV alone, other data demonstrate efficacy if ZDV is started rapidly following birth (6,70,71). In a study from North Carolina, the rate of infection among HIV-1–exposed infants who received only postpartum ZDV chemoprophylaxis was similar to that observed among infants who received no ZDV chemoprophylaxis (6). However, another epidemiologic study from New York State determined that administration of ZDV to the neonate for 6 weeks was associated with a significant reduction in transmission if the drug was initiated within 24 hours of birth (the majority of infants started within 12 hours) (70,71). Consistent with a possible preventive effect of rapid postexposure prophylaxis, a retrospective case-control study of health-care workers from the United States, France, and the United Kingdom who had nosocomial exposure to HIV-1–infected blood determined that postexposure use of ZDV was associated with reduced odds of contracting HIV-1 (adjusted odds ratio = 0.2; 95% CI = 0.1–0.6) (72). Several ongoing clinical trials are attempting to determine the optimal postexposure antiretroviral prophylaxis regimen for infants.

Perinatal HIV-1 Transmission and Maternal HIV-1 RNA Copy Number

The correlation of HIV-1 RNA levels with risk for disease progression in nonpregnant infected adults suggests that HIV-1 RNA should be monitored during pregnancy at least as often as recommended for persons who are not pregnant (i.e., every 3 to 4 months or approximately once each trimester). In addition, HIV-1 RNA levels should be evaluated at 34–36 weeks of gestation to allow discussion of options for mode of delivery based on HIV-1 RNA results and clinical circumstances.

Although no data indicate that pregnancy accelerates HIV-1 disease progression, longitudinal measurements of HIV-1 RNA levels during and after pregnancy have been evaluated in only a limited number of prospective cohort studies. In one cohort of 198 HIV-1–infected women, plasma HIV-1 RNA levels were higher at 6 months postpartum than during pregnancy in many women; this increase was observed in women regardless of ZDV use during and after pregnancy (73).

Initial data regarding the correlation of viral load with risk for perinatal transmission were conflicting, with some studies suggesting an absolute correlation between HIV-1 RNA copy number and risk of transmission (74). However, although higher HIV-1 RNA levels have been observed among women who transmitted HIV-1 to their infants, overlap in HIV-1 RNA copy number has been observed in women who transmitted and those who did not transmit the virus. Transmission has been observed across the entire range of HIV-1 RNA levels (including in women with HIV-1 RNA copy number below the limit of detection of the assay), and the predictive value of RNA copy number for transmission in an individual woman has been relatively poor (73,75,76). In PACTG 076, antenatal maternal HIV-1 RNA copy number was associated with HIV-1 transmission in women receiving placebo. In women receiving ZDV, the relationship was markedly attenuated and no longer statistically significant (52). An HIV-1 RNA threshold below which there was no risk for transmission was not identified; ZDV was effective in reducing transmission regardless of maternal HIV-1 RNA copy number (52,77).

More recent data from larger numbers of ZDV-treated infected pregnant women indicate that HIV-1 RNA levels correlate with risk of transmission even among women treated with antiretroviral agents (62,78–80). Although the risk for perinatal transmission in women with HIV-1 RNA below the level of assay quantitation appears to be extremely low, transmission from mother to infant has been reported among women with all levels of maternal HIV-1 RNA. Additionally, although HIV-1 RNA may be an important risk factor for transmission, other factors also appear to play a role (80–82).

Although there is a general correlation between viral load in plasma and in the genital tract, discordance has also been reported, particularly between HIV-1 proviral load in blood and genital secretions (83–86). If exposure to HIV-1 in the maternal genital tract during delivery is a risk factor for perinatal transmission, plasma HIV-1 RNA levels might not always be an accurate indicator of risk. Long-term changes in one compartment (such as can occur with antiretroviral treatment) may or may not be associated with comparable changes in other body compartments. Further studies are needed to determine the effect of antiretroviral drugs on genital tract

viral load and the association of such effects on the risk of perinatal HIV-1 transmission. In the short-course ZDV trial in Thailand, plasma and cervicovaginal HIV-1 RNA levels were reduced by ZDV treatment, and each independently correlated with perinatal transmission (87). The full ZDV chemoprophylaxis regimen, alone or in combination with other antiretroviral agents, including intravenous ZDV during delivery and the administration of ZDV to the infant for the first 6 weeks of life, should be discussed with and offered to all infected pregnant women regardless of their HIV-1 RNA level.

Results of epidemiologic and clinical trials suggest that women receiving highly active antiretroviral regimens that effectively reduce HIV-1 RNA to <1,000 copies/mL or undetectable levels have very low rates of perinatal transmission (27,61,69,88). However, since transmission can occur even at low or undetectable HIV-1 RNA copy numbers, RNA levels should not be a determining factor when deciding whether to use ZDV for chemoprophylaxis. Additionally, the efficacy of ZDV is not solely related to lowering viral load. In one study of 44 HIV-1–infected pregnant women, ZDV was effective in reducing transmission despite minimal effect on HIV-1 RNA levels (89). These results are similar to those observed in PACTG 076 (52). Antiretroviral prophylaxis reduces transmission even among women with HIV-1 RNA levels <1,000 copies/mL (90). Therefore, at a minimum, ZDV prophylaxis should be given even to women who have a very low or undetectable plasma viral load.

Preconception Counseling and Care for HIV-1–Infected Women of Childbearing Age

Many women infected with HIV-1 (nearly 60% in some centers) enter pregnancy with a known diagnosis, and nearly half of these women enter the first trimester of pregnancy receiving treatment with single or multiagent antiretroviral therapy (91). Additionally, as many as 40% of women who have begun antiretroviral therapy before their pregnancy might require adjustment of their therapeutic regimen during their pregnancy course.

The American College of Obstetrics and Gynecology advocates extending to all women of childbearing age the opportunity to receive preconception counseling as a component of routine primary medical care. It is recognized that >40% of pregnancies may be unintended and that the diagnosis of pregnancy most frequently occurs late in the first trimester when organogenesis is nearly completed. Preconception care can

identify risk factors for adverse maternal or fetal outcome (e.g., age, diabetes, hypertension), provide education and counseling targeted to the patient's individual needs, and treat or stabilize medical conditions before conception to optimize maternal and fetal outcomes (92).

For women with HIV-1 infection, preconception care must also focus on maternal infection status, viral load, immune status, and therapeutic regimen as well as education regarding perinatal transmission risks and prevention strategies, expectations for the child's future, and, where desired, effective contraception until the optimal maternal health status for pregnancy is achieved.

The following components of preconception counseling are recommended for HIV-1–infected women:

- selection of effective and appropriate contraceptive methods to reduce the likelihood of unintended pregnancy;
- education and counseling about perinatal transmission risks, strategies to reduce those risks, and potential effects of HIV-1 or treatment on pregnancy course and outcomes;
- initiation or modification of antiretroviral therapy:
 - avoid agents with potential reproductive toxicity for the developing fetus (e.g., efavirenz, hydroxyurea) (20),
 - choose agents effective in reducing the risk of perinatal HIV-1 transmission,
 - attain a stable, maximally suppressed maternal viral load,
 - evaluate and control for therapy-associated side effects that may adversely affect maternal/fetal health outcomes (e.g., hyperglycemia, anemia, hepatic toxicity),
- evaluation and appropriate prophylaxis for opportunistic infections and administration of medical immunizations (e.g., influenza, pneumococcal, or hepatitis B vaccines) as indicated;
- optimization of maternal nutritional status;
- institution of the standard measures for preconception evaluation and management (e.g., assessment of reproductive and familial genetic history, screening for infectious diseases/sexually transmitted diseases, and initiation of folic acid supplementation);
- screening for maternal psychological and substance abuse disorders; and
- planning for perinatal consultation if desired or indicated.

HIV-1–infected women of childbearing potential receive primary health-care services in various clinical settings, e.g., family planning, family medicine, internal medicine, obstetrics/gynecology. It is imperative that primary health-care providers consider the fundamental principles of preconception counseling an integral component of comprehensive primary health care for improving maternal/child health outcomes.

General Principles Regarding the Use of Antiretroviral Agents in Pregnancy

Medical care of the HIV-1–infected pregnant woman requires coordination and communication between the HIV specialist caring for the woman when she is not pregnant and her obstetrician. Decisions regarding use of antiretroviral drugs during pregnancy should be made by the woman after discussion with her health-care provider about the known and unknown benefits and risks of therapy. Initial evaluation of an infected pregnant woman should include an assessment of HIV-1 disease status and recommendations regarding antiretroviral treatment or alteration of her current antiretroviral regimen.

This assessment should include the following:

- evaluation of the degree of existing immunodeficiency determined by CD4⁺ count;
- risk for disease progression as determined by the level of plasma RNA;
- history of prior or current antiretroviral therapy;
- gestational age; and
- supportive care needs.

Decisions regarding initiation of therapy should be the same for women who are not currently receiving antiretroviral therapy and for women who are not pregnant, with the additional consideration of the potential impact of such therapy on the fetus and infant (14). Similarly, for women currently receiving antiretroviral therapy, decisions regarding alterations in therapy should involve the same considerations as those used for women who are not pregnant. The three-part ZDV chemoprophylaxis regimen, alone or in combination with other antiretroviral agents, should be discussed with and offered to all infected pregnant women to reduce the risk for perinatal HIV-1 transmission.

Decisions regarding the use and choice of antiretroviral drugs during pregnancy are complex; several competing factors influencing risk and benefit must be weighed. Discussion regarding the use of antiretroviral drugs during pregnancy should include the following:

- what is known and not known about the effects of such drugs on the fetus and newborn, including lack of long-term outcome data on the use of any of the available antiretroviral drugs during pregnancy;
- what treatment is recommended for the health of the HIV-1–infected woman; and
- the efficacy of ZDV for reduction of perinatal HIV-1 transmission.

Results from preclinical and animal studies and available clinical information about use of the various antiretroviral agents during pregnancy also should be discussed (20). The hypothetical risks of these drugs during pregnancy should be placed in perspective with the proven benefit of antiretroviral therapy for the health of the infected woman and the benefit of ZDV chemoprophylaxis for reducing the risk for HIV-1 transmission to her infant.

Discussion of treatment options should be noncoercive, and the final decision regarding use of antiretroviral drugs is the responsibility of the woman. Decisions regarding use and choice of antiretroviral drugs for persons who are not pregnant are becoming increasingly complicated as the standard of care moves toward simultaneous use of multiple antiretroviral drugs to suppress viral replication below detectable limits. These decisions are further complicated in pregnancy because the long-term consequences for the infant who has been exposed to antiretroviral drugs in utero are unknown. A woman's decision to refuse treatment with ZDV or other drugs should not result in punitive action or denial of care. Further, use of ZDV alone should not be denied to a woman who wishes to minimize exposure of the fetus to other antiretroviral drugs and therefore, after counseling, chooses to receive only ZDV during pregnancy to reduce the risk for perinatal transmission.

A long-term treatment plan should be developed after discussion between the patient and the health-care provider and should emphasize the importance of adherence to any prescribed antiretroviral regimen. Depending on individual circumstances, provision of support services, mental health services, and drug abuse treatment may be required. Coordination of services among prenatal care providers, primary care and HIV-1 specialty care providers, mental health and drug abuse treatment services, and public assistance programs is essential to ensure adherence of the infected woman to antiretroviral treatment regimens.

General counseling should include what is known regarding risk factors for perinatal transmission. Cigarette smoking, illicit drug use, and unprotected sexual intercourse with multiple partners during pregnancy have been associated with risk for perinatal HIV-1 transmission (93–97), and discontinuing these practices might reduce this risk. In addition, CDC recommends that infected women in the United States refrain from breastfeeding to avoid postnatal transmission of HIV-1 to their infants through breast milk (3,98); these recommendations also should be followed by women receiving antiretroviral therapy. Passage of antiretroviral drugs into breast milk has been evaluated for only a few antiretroviral drugs. ZDV, 3TC, and nevirapine can be detected in the breast milk of women, and ddI, d4T, abacavir, delavirdine, indinavir,

ritonavir, saquinavir and amprenavir can be detected in the breast milk of lactating rats. Limited data are available regarding either the efficacy of antiretroviral therapy for the prevention of postnatal transmission of HIV-1 through breast milk or the toxicity of long-term antiretroviral exposure of the infant through breast milk.

Women who must temporarily discontinue therapy because of pregnancy-related hyperemesis should not resume therapy until sufficient time has elapsed to ensure that the drugs will be tolerated. To reduce the potential for emergence of resistance, if therapy requires temporary discontinuation for any reason during pregnancy, all drugs should be stopped and reintroduced simultaneously.

Recommendations for Antiretroviral Chemoprophylaxis to Reduce Perinatal HIV-1 Transmission

The following recommendations for use of antiretroviral chemoprophylaxis to reduce the risk for perinatal transmission are based on situations that may be commonly encountered in clinical practice (Box 1), with relevant considerations highlighted in the subsequent discussion sections. These recommendations are only guidelines, and flexibility should be exercised according to the patient's individual circumstances. In the 1994 recommendations (2), six clinical situations were delineated on the basis of maternal CD4⁺ count, weeks of gestation, and prior antiretroviral use. Because current data indicate that the PACTG 076 ZDV regimen also is effective for women with advanced disease, low CD4⁺ count, and prior ZDV therapy, clinical situations based on CD4⁺ count and prior ZDV use are not presented. Additionally, because data indicate that most transmission occurs near the time of or during delivery, ZDV chemoprophylaxis is recommended regardless of weeks of gestation; thus, clinical situations based on weeks of gestation also are not presented.

The antenatal dosing regimen in PACTG 076 (100 mg administered orally five times daily) (Table 1) was selected on the basis of the standard ZDV dosage for adults at the time of the study. However, recent data have indicated that administration of ZDV three times daily will maintain intracellular ZDV triphosphate at levels comparable with those observed with more frequent dosing (99–101). Comparable clinical response also has been observed in some clinical trials among persons receiving ZDV twice daily (102–104). Thus, the current standard ZDV dosing regimen for adults is 200 mg three times daily, or 300 mg twice daily. Because the mechanism by which ZDV reduces perinatal transmission is not known, these

BOX 1. Clinical situations and recommendations for use of antiretroviral drugs to reduce perinatal human immunodeficiency virus type 1 (HIV-1) transmission

1. HIV-1–infected pregnant women who have not received prior antiretroviral therapy

- Pregnant women with HIV-1 infection must receive standard clinical, immunologic, and virologic evaluation. Recommendations for initiation and choice of antiretroviral therapy should be based on the same parameters used for persons who are not pregnant, although the known and unknown risks and benefits of such therapy during pregnancy must be considered and discussed.
- The three-part zidovudine (ZDV) chemoprophylaxis regimen, initiated after the first trimester, should be recommended for all pregnant women with HIV-1 infection regardless of antenatal HIV-1 RNA copy number to reduce the risk for perinatal transmission.
- The combination of ZDV chemoprophylaxis with additional antiretroviral drugs for treatment of HIV-1 infection is recommended for infected women whose clinical, immunologic, or virologic status requires treatment or whose HIV-1 RNA is >1,000 copies/mL regardless of clinical or immunologic status.
- Women who are in the first trimester of pregnancy may consider delaying initiation of therapy until after 10–12 weeks' gestation.

2. HIV-1–infected women receiving antiretroviral therapy during the current pregnancy

- HIV-1 infected women receiving antiretroviral therapy whose pregnancy is identified after the first trimester should continue therapy. ZDV should be a component of the antenatal antiretroviral treatment regimen after the first trimester whenever possible, although this may not always be feasible.
- Women receiving antiretroviral therapy whose pregnancy is recognized during the first trimester should be counseled regarding the benefits and potential risks of antiretroviral administration during this period, and continuation of therapy should be considered. If therapy is discontinued during the first trimester, all drugs should be stopped and reintroduced simultaneously to avoid the development of drug resistance.
- Regardless of the antepartum antiretroviral regimen, ZDV administration is recommended during the intrapartum period and for the newborn.

3. HIV-1–infected women in labor who have had no prior therapy

- Several effective regimens are available for women who have had no prior therapy (Table 3):
 - a single dose nevirapine at the onset of labor followed by a single dose of nevirapine for the newborn at age 48 hours,
 - oral ZDV and lamivudine (3TC) during labor, followed by 1 week of oral ZDV-3TC for the newborn,
 - intrapartum intravenous ZDV followed by 6 weeks of ZDV for the newborn, or
 - the 2-dose nevirapine regimen combined with intrapartum intravenous ZDV and 6 weeks of ZDV for the newborn.
- In the immediate postpartum period, the woman should have appropriate assessments (e.g., CD4⁺ T-lymphocyte count and HIV-1 RNA copy number) to determine whether antiretroviral therapy is recommended for her own health.

4. Infants born to mothers who have received no antiretroviral therapy during pregnancy or intrapartum

- The 6-week neonatal component of the ZDV chemoprophylactic regimen should be discussed with the mother and offered for the newborn.
- ZDV should be initiated as soon as possible after delivery, preferably within 6–12 hours of birth.
- Some clinicians might use ZDV in combination with other antiretroviral drugs, particularly if the mother is known or suspected to have ZDV-resistant virus. However, the efficacy of this approach for prevention of transmission is unknown, and appropriate dosing regimens for neonates are incompletely defined.
- In the immediate postpartum period, the woman should undergo appropriate assessments (e.g., CD4⁺ count and HIV-1 RNA copy number) to determine if antiretroviral therapy is required for her own health. The infant should undergo early diagnostic testing so that if he or she is HIV infected, treatment can be initiated as soon as possible.

Note: Discussion of treatment options and recommendations should be noncoercive, and the final decision regarding use of antiretroviral drugs is the responsibility of the woman. A decision to not accept treatment with ZDV or other drugs should not result in punitive action or denial of care. Use of ZDV should not be denied to a woman who wishes to minimize exposure of the fetus to other antiretroviral drugs and who therefore chooses to receive only ZDV during pregnancy to reduce the risk for perinatal transmission.

dosing regimens may not have equivalent efficacy to that observed in PACTG 076. However, a regimen of two or three times daily is expected to increase adherence to the regimen.

The recommended ZDV dosage for infants was derived from pharmacokinetic studies performed among full-term infants (105). ZDV is primarily cleared through hepatic glucuronidation to an inactive metabolite. The glucuronidation metabolic enzyme system is immature in neonates, leading to prolonged ZDV half-life and clearance compared with older infants (ZDV half-life: 3.1 hours versus 1.9 hours; clearance: 10.9 versus 19.0 mL/minute/kg body weight, respectively). Because premature infants have even greater immaturity in hepatic metabolic function than full-term infants, further prolongation of clearance may be expected. In a study of 15 premature infants who were at 26–33 weeks' gestation and who received different ZDV dosing regimens, mean ZDV half-life was 7.2 hours and mean clearance was 2.5 mL/minute/kg body weight during the first 10 days of life (106). At a mean age of 18 days, a decrease in half-life (4.4 hours) and increase in clearance (4.3 mL/minute/kg body weight) were found. The appropriate ZDV dosage for premature infants has not been defined but is being evaluated in a phase I clinical trial among premature infants <34 weeks' gestation. The dosing regimen being studied is 1.5 mg/kg body weight orally or intravenously every 12 hours for the first 2 weeks of life; for infants aged 2 to 6 weeks, the dose is increased to 2 mg/kg body weight every 8 hours.

Clinical Situations and Recommendations for Use of Antiretroviral Prophylaxis

1. HIV-1-infected pregnant women who have not received prior antiretroviral therapy

Recommendation. Pregnant women with HIV-1 infection must receive standard clinical, immunologic, and virologic evaluation. Recommendations for initiation and choice of antiretroviral therapy should be based on the same parameters used for persons who are not pregnant, although the known and unknown risks and benefits of such therapy during pregnancy must be considered and discussed. The three-part ZDV chemoprophylaxis regimen, initiated after the first trimester, should be recommended for all pregnant women with HIV-1 infection regardless of antenatal HIV-1 RNA copy number to reduce the risk for perinatal transmission. The combination of ZDV chemoprophylaxis with additional antiretroviral drugs for treatment of HIV-1 infection is recommended for infected women whose clinical, immunologic, or virologic status requires treatment or whose HIV-1 RNA is $\geq 1,000$ copies/

mL regardless of their clinical or immunologic status. Women who are in the first trimester of pregnancy may consider delaying initiation of therapy until after 10–12 weeks' gestation.

Discussion. When ZDV is administered in the three-part PACTG 076 regimen, perinatal transmission is reduced by approximately 70%. Although the mechanism by which ZDV reduces transmission is not known, protection is likely multifactorial. Preexposure prophylaxis of the infant is provided by passage of ZDV across the placenta so that inhibitory levels of the drug are present in the fetus during the birth process. Although placental passage of ZDV is excellent, that of other antiretroviral drugs is variable (Table 2). Therefore, when combination antiretroviral therapy is initiated during pregnancy, ZDV should be included as a component of antenatal therapy whenever possible. Because the mechanism by which ZDV reduces transmission is not known, the intrapartum and newborn ZDV components of the chemoprophylactic regimen should be administered to reduce perinatal HIV-1 transmission. If a woman does not receive ZDV as a component of her antenatal antiretroviral regimen, intrapartum and newborn ZDV should still be recommended.

Because of the evolving and complex nature of the management of HIV-1 infection, a specialist with experience in the treatment of pregnant women with HIV-1 infection should be involved in their care. Women should be informed that potent combination antiretroviral regimens have substantial benefit for their own health and may provide enhanced protection against perinatal transmission. Several studies have indicated that for women with low or undetectable HIV-1 RNA levels (e.g., <1,000 copies/mL) rates of perinatal transmission are extremely low, particularly when they have received antiretroviral therapy (61,78,79). However, there is no threshold below which lack of transmission can be assured, and the long-term effects of in utero exposure to multiple antiretroviral drugs are unknown. Decisions regarding the use and choice of an antiretroviral regimen should be individualized based on discussion with the woman about the following factors:

- her risk for disease progression and the risks and benefits of delaying initiation of therapy;
- possible benefit of lowering viral load for reducing perinatal transmission;
- potential drug toxicities and interactions with other drugs
- the need for strict adherence to the prescribed drug schedule to avoid the development of drug resistance;
- unknown long-term effects of in utero drug exposure on the infant; and
- preclinical, animal, and clinical data relevant to use of the currently available antiretroviral agents during pregnancy.

Because the period of organogenesis (when the fetus is most susceptible to potential teratogenic effects of drugs) is during the first 10 weeks of gestation and the risks of antiretroviral therapy during that period are unknown, women in the first trimester of pregnancy might wish to delay initiation of therapy until after 10–12 weeks' gestation. This decision should be carefully considered by the health-care provider and the patient; a discussion should include an assessment of the woman's health status, the benefits and risks of delaying initiation of therapy for several weeks, and the fact that most perinatal HIV-1 transmission likely occurs late in pregnancy or during delivery. Treatment with efavirenz should be avoided during the first trimester because significant teratogenic effects in rhesus macaques were seen at drug exposures similar to those representing human exposure (Table 2) (20). Hydroxyurea is a potent teratogen in a variety of animal species and should also be avoided during the first trimester.

When initiation of antiretroviral therapy is considered optional on the basis of current guidelines for treatment of nonpregnant persons (14), infected pregnant women should be counseled regarding the potential benefits of standard combination therapy and should be offered such therapy, including the three-part ZDV chemoprophylaxis regimen. Although such women are at low risk for clinical disease progression if combination therapy is delayed, antiretroviral therapy that successfully reduces HIV-1 RNA to levels <1,000 copies/mL may substantially lower the risk of perinatal HIV-1 transmission and lessen the need for consideration of elective cesarean delivery as an intervention to reduce transmission risk.

When combination therapy is administered, the regimen should be chosen from those recommended for nonpregnant adults (14). Dual nucleoside analog therapy without the addition of either a protease inhibitor or nonnucleoside reverse transcriptase inhibitor is not recommended for nonpregnant adults because of the potential for inadequate viral suppression and rapid development of resistance (107). For pregnant women not meeting the criteria for antiretroviral therapy for their own health, and receiving antiretroviral drugs only for prevention of perinatal transmission (e.g., those with HIV-1 RNA <1,000 copies/mL), dual nucleoside therapy may be considered in selected circumstances. If combination therapy is given principally to reduce perinatal transmission and would have been optional if the woman were not pregnant, consideration may be given to discontinuing therapy postnatally, with the option to reinstate treatment according to standard criteria for nonpregnant women. If drugs are discontinued postnatally, all drugs should be stopped simultaneously. Discussion regarding the decision to continue or stop combination therapy postpartum should occur before beginning therapy during pregnancy.

Antiretroviral prophylaxis has been beneficial in preventing perinatal transmission even for infected pregnant women with HIV-1 RNA levels <1,000 copies/mL. In a meta-analysis of factors associated with perinatal transmission among women whose infants were infected despite the women's having HIV-1 RNA <1,000 copies/mL at or near delivery, transmission was only 1.0% among women receiving antenatal antiretroviral therapy (primarily ZDV alone) compared with 9.8% among those receiving no antenatal therapy (90). Therefore, use of antiretroviral prophylaxis is recommended for all pregnant women with HIV-1 infection regardless of antenatal HIV-1 RNA level.

The time-limited use of ZDV alone during pregnancy for chemoprophylaxis against perinatal transmission is controversial. Standard combination antiretroviral regimens for treatment of HIV-1 infection should be discussed and should be offered to all pregnant women with HIV-1 infection regardless of viral load; they are recommended for all pregnant women with HIV-1 RNA levels \geq 1,000 copies/mL. Some women may wish to restrict exposure of their fetus to antiretroviral drugs during pregnancy and still reduce the risk of transmitting HIV-1 to their infant. Additionally, for women with HIV-1 RNA levels <1,000 copies/mL, time-limited use of ZDV during the second and third trimesters of pregnancy is less likely to induce the development of resistance because of the limited viral replication existing in the patient and the time-limited exposure to the antiretroviral drug. For example, the development of ZDV resistance was unusual among the healthy population of women who participated in PACTG 076 (108). The use of ZDV chemoprophylaxis alone (or, in selected circumstances, dual nucleosides) during pregnancy might be an appropriate option for these women.

2. HIV-1-infected women receiving antiretroviral therapy during the current pregnancy

Recommendation. HIV-1 infected women receiving antiretroviral therapy whose pregnancy is identified after the first trimester should continue therapy. ZDV should be a component of the antenatal antiretroviral treatment regimen after the first trimester whenever possible, although this may not always be feasible. Women receiving antiretroviral therapy whose pregnancy is recognized during the first trimester should be counseled regarding the benefits and potential risks of antiretroviral administration during this period, and continuation of therapy should be considered. If therapy is discontinued during the first trimester, all drugs should be stopped and reintroduced simultaneously to avoid the development of drug resistance. Regardless of the antepartum antiretroviral

regimen, ZDV administration is recommended during the intrapartum period and for the newborn.

Discussion. Women who have been receiving antiretroviral treatment for their HIV-1 infection should continue treatment during pregnancy. Discontinuation of therapy could lead to an increase in viral load, which could result in decline in immune status and disease progression as well as adverse consequences for both the fetus and the woman.

Although ZDV should be a component of the antenatal antiretroviral treatment whenever possible, there may be circumstances, such as the occurrence of significant ZDV-related toxicity, when this is not feasible. Additionally, women receiving an antiretroviral regimen that does not contain ZDV but who have HIV-1 RNA levels that are consistently very low or undetectable (e.g., <1,000 copies/mL) have a very low risk of perinatal transmission (61), and there may be concerns that the addition of ZDV to the current regimen could compromise adherence to treatment.

The maternal antenatal antiretroviral treatment regimen should be continued on schedule as much as possible during labor to provide maximal virologic effect and to minimize the chance of development of drug resistance. If a woman has not received ZDV as a component of her antenatal therapeutic antiretroviral regimen, intravenous ZDV should still be administered during the intrapartum period whenever feasible. ZDV and d4T should not be administered together because of potential pharmacologic antagonism; options for women receiving oral d4T as part of their antenatal therapy include either continuation of oral d4T during labor without intravenous ZDV or withholding oral d4T during the period of intravenous ZDV administration during labor. Additionally, the infant should receive the standard 6-week course of ZDV.

For women with suboptimal suppression of HIV-1 RNA (i.e., $\geq 1,000$ copies/mL) near the time of delivery despite having received prenatal ZDV prophylaxis with or without combination antiretroviral therapy, it is not known if administration of additional antiretroviral drugs during labor and delivery provides added protection against perinatal transmission. In the HIVNET 012 study among Ugandan women who had not received antenatal antiretroviral therapy, a 2-dose nevirapine regimen (single dose to the woman at the onset of labor and single dose to the infant at age 48 hours) significantly reduced perinatal transmission compared with a very short intrapartum/1 week postpartum ZDV regimen (65). For women in the United States, Europe, Brazil, and the Bahamas receiving antenatal antiretroviral therapy, addition of the 2-dose nevirapine regimen did not result in lower transmission rates (69). Given the lack of further reduction of transmission with nevirapine added to one of the standard

antepartum regimens used in developed countries and the potential development of nevirapine resistance (See Antiretroviral Drug Resistance and Resistance Testing in Pregnancy), addition of nevirapine during labor for women already receiving antiretroviral therapy is not recommended in the United States.

Women receiving antiretroviral therapy may realize they are pregnant early in gestation and want to consider temporarily stopping antiretroviral treatment until after the first trimester because of concern for potential teratogenicity. Data are insufficient to support or refute the teratogenic risk of antiretroviral drugs when administered during the first 10 weeks of gestation; certain drugs are of more concern than others (Table 2) (20). The decision to continue therapy during the first trimester should be carefully considered by the clinician and the pregnant woman. Discussions should include considerations such as gestational age of the fetus; the woman's clinical, immunologic, and virologic status; and the known and unknown potential effects of the antiretroviral drugs on the fetus. If antiretroviral therapy is discontinued during the first trimester, all agents should be stopped and restarted simultaneously in the second trimester to avoid the development of drug resistance. No data are available to address whether temporary discontinuation of therapy is harmful for the woman or fetus.

Health-care providers might consider administering ZDV in combination with other antiretroviral drugs to newborns of women with a history of prior antiretroviral therapy, particularly in situations in which the woman is infected with HIV-1 with documented high-level ZDV resistance, has had disease progression while receiving ZDV, or has had extensive prior ZDV monotherapy. The efficacy of this approach is unknown but would be analogous to the use of multiple agents for postexposure prophylaxis for adults after inadvertent exposure. However, the appropriate dosage and short- and long-term safety of many antiretroviral agents in the neonate has not been established. The half-lives of ZDV, 3TC, and nevirapine are prolonged during the neonatal period because of immature liver metabolism and renal function, requiring specific dosing adjustments when these agents are administered to neonates. Optimal dosages for protease inhibitors in the neonatal period are still under study. The infected woman should be counseled regarding the theoretical benefit of combination antiretroviral drugs for the neonate, potential risks, and available data on appropriate dosing. She should also be informed that using antiretroviral drugs in addition to ZDV for prophylaxis of newborns is of unknown efficacy in reducing risk of perinatal transmission.

3. HIV-1–Infected Women in Labor Who Have Had No Prior Therapy

Recommendation. Several effective regimens are available for intrapartum therapy for women who have had no prior therapy (Table 3):

- a single dose of nevirapine at onset of labor followed by a single dose of nevirapine for the newborn at age 48 hours;
- oral ZDV and 3TC during labor, followed by 1 week of oral ZDV-3TC for the newborn;

- intrapartum intravenous ZDV followed by 6 weeks of ZDV for the newborn; and
- the 2-dose nevirapine regimen combined with intrapartum intravenous ZDV and 6 weeks of ZDV for the newborn.

In the immediate postpartum period, the woman should have appropriate assessments (e.g., CD4⁺ count and HIV-1 RNA copy number) to determine whether antiretroviral therapy is recommended for her own health.

TABLE 3. Comparison of intrapartum/postpartum regimens for HIV-1–infected women in labor who have had no prior antiretroviral therapy

Drug regimen	Source of evidence	Maternal intrapartum	Infant postpartum	Transmission	Advantages	Disadvantages
Nevirapine	Clinical trial, Africa; compared with oral ZDV* given intrapartum and for 1 week to the infant	Single 200-mg oral dose at onset of labor	Single 2-mg/kg oral dose at age 48–72 hours [†]	Transmission at 6 weeks 12% with nevirapine vs. 21% with ZDV, a 47% reduction (95% CI*, 20–64%)	Inexpensive Oral regimen Simple, easy to administer Can give directly observed treatment	Unknown efficacy if mother has nevirapine-resistant virus
ZDV-3TC*	Clinical trial, Africa; compared with placebo	ZDV 600 mg orally at onset of labor, followed by 300 mg orally every 3 hours until delivery AND 3TC 150 mg orally at onset of labor, followed by 150 mg orally every 12 hours until delivery	ZDV 4 mg/kg orally every 12 hours AND 3TC 2 mg/kg orally every 12 hours for 7 days	Transmission at 6 weeks 9% with ZDV-3TC vs. 15% with placebo, a 40% reduction	Oral regimen Adherence easier than 6 weeks of ZDV	Potential toxicity of multiple drug exposure
ZDV	Epidemiologic data, U.S.; compared with no ZDV treatment	2-mg/kg intravenous bolus, followed by continuous infusion of 1 mg/kg/hr until delivery	2 mg/kg orally every 6 hours for 6 weeks	Transmission 10% with ZDV vs. 27% with no ZDV treatment, a 62% reduction (95% CI, 19–82%)	Has been standard recommendation before clinical trial results	Requires intravenous administration and availability of ZDV intravenous formulation; Adherence to 6-week infant regimen
ZDV-nevirapine	Theoretical	ZDV 2-mg/kg intravenous bolus, followed by continuous infusion of 1 mg/kg/hr until delivery AND Nevirapine single 200-mg oral dose at onset of labor	ZDV 2 mg/kg orally every 6 hours for 6 weeks AND Nevirapine single 2-mg/kg oral dose at age 48–72 hours	No data	Potential benefit if maternal virus is resistant to either nevirapine or ZDV; Synergistic inhibition of HIV replication with combination in vitro.	Requires intravenous administration and availability of ZDV intravenous formulation; Adherence to 6-week infant ZDV regimen; Unknown efficacy and limited toxicity data.

* ZDV, zidovudine; CI, confidence interval; 3TC, lamivudine.

[†] If the mother received nevirapine less than 1 hour before delivery, the infant should be given 2 mg/kg oral nevirapine as soon as possible after birth and again at 48–72 hours.

Discussion. Although intrapartum antiretroviral medications will not prevent perinatal transmission that occurs before labor, most transmission occurs near to or during labor and delivery. Preexposure prophylaxis for the fetus can be provided by giving the mother a drug that rapidly crosses the placenta to produce systemic antiretroviral drug levels in the fetus during intensive exposure to HIV-1 in maternal genital secretions and blood during birth.

Several intrapartum/neonatal antiretroviral prophylaxis regimens are applicable for women in labor who have had no prior antiretroviral therapy (Table 3). Two regimens, one using 2 doses of nevirapine (one each for the mother and infant) and the other a combination of ZDV and 3TC, were shown to reduce perinatal transmission in randomized clinical trials among breastfeeding women, and available epidemiologic data suggest the efficacy of a third, ZDV-only regimen. The fourth regimen, combining ZDV with nevirapine, is based upon theoretical considerations.

In the HIVNET 012 trial, conducted in Uganda, a regimen consisting of a single dose of oral nevirapine given to the woman at onset of labor and a single dose to the infant at age 48 hours was compared with oral ZDV given to the woman every 3 hours during labor and postnatally to the infant for 7 days (Table 3). At age 6 weeks, the rates of transmission were 12% (95% CI = 8%–16%) in the nevirapine arm versus 21% (95% CI = 16%–26%) in the ZDV arm, a 47% reduction (95% CI = 20%–64%) in transmission (65). No serious short-term toxicity was observed in either group. Because no placebo group was included, no conclusions can be drawn regarding the efficacy of the intrapartum/1-week neonatal ZDV regimen versus no treatment.

In the PETRA trial, conducted in Uganda, South Africa, and Tanzania, ZDV and 3TC were administered orally intrapartum and to the woman and infant for 7 days postnatally. Oral ZDV and 3TC were administered at the onset of labor and continued until delivery (Table 3). Postnatally, the woman and infant received ZDV and 3TC every 12 hours for 7 days. At age 6 weeks, the rates of transmission were 9% in the ZDV-3TC arm versus 15% in the placebo arm, a 40% reduction in transmission (64). However, no differences in transmission were observed when oral ZDV and 3TC were administered only during the intrapartum period (transmission of 14% in the ZDV-3TC arm versus 15% in the placebo arm), indicating that some postexposure prophylaxis is needed, at least in breastfeeding settings.

These clinical trials were conducted in Africa, where the majority of women breastfeed their infants. Because HIV-1 can be transmitted by breast milk and the highest risk period for such transmission is the first few months of life (109), the absolute transmission rates observed in the African trials may

not be comparable to what might be observed with these regimens in HIV-1–infected women in the United States, where breastfeeding is not recommended. However, comparison of the percentage of reduction in transmission at early timepoints (e.g., 4–6 weeks) may be applicable. In the effective arms of the PETRA trial, antiretroviral drugs were administered postnatally to both the mother and the infant to reduce the risk of early transmission through breast milk. In the United States, administration of ZDV-3TC to the mother postnatally in addition to the infant would not be required for prophylaxis against transmission because HIV-1–infected women are advised not to breastfeed their infants (although ZDV-3TC might be indicated as part of a combination postnatal treatment regimen for the woman).

Epidemiologic data from New York State indicate that intravenous maternal intrapartum ZDV followed by oral ZDV for 6 weeks to the infant may significantly reduce transmission compared with no treatment (Table 3). Transmission rates were 10% (95% CI = 3%–22%) with intrapartum and neonatal ZDV compared with 27% (95% CI = 21%–33%) without ZDV, a 62% reduction in risk (95% CI = 19%–82%) (70,71). Similarly, in an epidemiologic study in North Carolina, intravenous intrapartum and 6-week oral neonatal ZDV treatment was associated with a transmission rate of 11%, compared with 31% without therapy (6). However, intrapartum ZDV combined with very short-term ZDV administration to infants postnatally, e.g., the 1-week postnatal infant ZDV course in HIVNET 012 (65), has not proved effective to date. This underscores the necessity of recommending a full 6-week course of infant treatment when ZDV alone is used.

No data are available to address the relative efficacy of these three intrapartum/neonatal antiretroviral regimens for prevention of transmission. In the absence of data to suggest the superiority of one or more of the possible regimens, choice should be based upon the specific circumstances of each woman. The 2-dose nevirapine regimen offers the advantage of lower cost, the possibility of directly observed therapy and increased adherence compared with the other two regimens. In a clinical trial (SAINT) in South Africa, which compared the 2-dose nevirapine and the intrapartum/postpartum ZDV-3TC regimens, no significant differences were observed between the two regimens in terms of efficacy in reducing transmission or in maternal and infant toxicity (66).

It has not been determined if combining intravenous intrapartum/6-week neonatal oral ZDV with the 2-dose nevirapine regimen will provide additional benefit over that observed with each regimen alone. Clinical trial data have established that combination therapy is superior to single-drug therapy for

treatment of persons with established infection and that infants born to women in labor who have not received any antiretroviral therapy are at high risk for infection. The 2-dose nevirapine regimen had no serious short-term drug-associated toxicity in the 313 mother–infant pairs exposed to the regimen in the HIVNET 012 trial. Nevirapine and ZDV are synergistic in inhibiting HIV-1 replication *in vitro* (110), and both nevirapine and ZDV rapidly cross the placenta to achieve drug levels in the infant nearly equal to those in the mother. In contrast to ZDV, nevirapine can decrease plasma HIV-1 RNA concentration by at least 1.3 log by 7 days after a single dose (111) and is active immediately against intracellular and extracellular virus (112). However, nevirapine resistance can be induced by a single mutation at codon 181, whereas high-level resistance to ZDV requires several mutations. Nevirapine resistance mutations were detected at 6 weeks postpartum in 19% of antiretroviral naive women and 15% of women receiving antiretroviral drugs during pregnancy who received single-dose nevirapine during labor (See Antiretroviral Drug Resistance and Resistance Testing in Pregnancy).

A theoretical benefit of combining the intrapartum/neonatal ZDV and nevirapine regimens would be the efficacy of this combination if the woman had acquired infection with HIV-1 that is resistant to either ZDV or nevirapine. Perinatal transmission of antiretroviral drug-resistant virus has been reported but appears to be unusual (6,113,114). Virus with low-level ZDV resistance may be less likely to establish infection than wild-type virus, and transmission may not occur even when maternal virus has high-level ZDV resistance (114–117). Since the prevalence of drug-resistant virus is an evolving phenomenon, surveillance is needed to determine this prevalence in pregnant women over time and the risk of transmission of resistant viral strains. The potential benefits of combination prophylaxis with intrapartum/neonatal nevirapine and ZDV must be weighed against the increased cost, possible problems with nonadherence, potential short- and long-term toxicity, including the risk of emergence of nevirapine-resistant virus, and the lack of definitive data to show that combining the two intrapartum/postpartum regimens offers any additional benefit for prevention of transmission over the use of either drug alone.

4. Infants Born to Mothers Who Have Received No Antiretroviral Therapy During Pregnancy or Intrapartum

Recommendation. The 6-week neonatal component of the ZDV chemoprophylactic regimen should be discussed with the mother and offered for the newborn. ZDV should be initiated as soon as possible after delivery, preferably within

6–12 hours of birth. Some clinicians may use ZDV in combination with other antiretroviral drugs, particularly if the mother is known or suspected to have ZDV-resistant virus. However, the efficacy of this approach for prevention of transmission is unknown, and appropriate dosing regimens for neonates are incompletely defined. In the immediate postpartum period, the woman should undergo appropriate assessments (e.g., CD4⁺ count and HIV-1 RNA copy number) to determine if antiretroviral therapy is required for her own health. The infant should undergo early diagnostic testing so that if he or she is HIV-1 infected, treatment can be initiated as soon as possible.

Discussion. Definitive data are not available to address whether ZDV administered only during the neonatal period would reduce the risk of perinatal transmission. Epidemiologic data from a New York State study indicate a decline in transmission when infants were given ZDV for the first 6 weeks of life compared with no prophylaxis (70,71). Transmission rates were 9% (95% CI = 4.1%–17.5%) with ZDV prophylaxis of newborns only (initiated within 48 hours after birth) versus 18% (95% CI = 7.7%–34.3%) with prophylaxis initiated after 48 hours, and 27% (95% CI = 21%–33%) with no ZDV prophylaxis (70). Epidemiologic data from North Carolina did not demonstrate a benefit of ZDV for newborns only compared with no prophylaxis (6). Transmission rates were 27% (95% CI = 8%–55%) with prophylaxis of newborns only and 31% (95% CI = 24%–39%) with no prophylaxis. The timing of initiation of infant prophylaxis was not defined in this study. Data from a case-control study of postexposure prophylaxis of health-care workers who had nosocomial percutaneous exposure to blood from HIV-1-infected persons indicate that ZDV administration was associated with a 79% reduction in the risk for HIV-1 seroconversion following exposure (72). Postexposure prophylaxis also has prevented retroviral infection in some studies involving animals (118–120).

The interval during which benefit can be gained from postexposure prophylaxis is undefined. When prophylaxis was delayed beyond 48 hours after birth in the New York State study, no efficacy could be demonstrated. For most infants in this study, prophylaxis was initiated within 24 hours (71). Data from studies of animals indicate that the longer the delay in institution of prophylaxis, the less likely that infection will be prevented. In most studies of animals, antiretroviral prophylaxis initiated 24–36 hours after exposure has usually not been effective for preventing infection, although later administration has been associated with decreased viremia (118–120). In cats, ZDV treatment initiated within the first 4 days after challenge with feline leukemia virus afforded protection, whereas treatment initiated 1 week postexposure did not (121).

The relevance of these animal studies to prevention of perinatal HIV-1 transmission in humans is unknown. HIV-1 infection is established in most infected infants by age 1–2 weeks. In a study of 271 infected infants, HIV-1 DNA polymerase chain reaction (PCR) was positive in 38% of samples from infants tested within 48 hours of birth. No substantial change in diagnostic sensitivity was observed within the first week of life, but detection increased rapidly during the second week of life, reaching 93% by age 14 days (122). Initiation of postexposure prophylaxis after age 2 days is not likely to be efficacious in preventing transmission, and by age 14 days, infection would already be established in most infants.

When the mother has received neither the antenatal nor intrapartum parts of the three-part ZDV regimen, administration of antiretroviral drugs to the newborn provides chemoprophylaxis only after HIV-1 exposure has already occurred. Some clinicians view this situation as analogous to nosocomial postexposure prophylaxis and may wish to provide ZDV in combination with one or more other antiretroviral agents. Such a decision must be accompanied by a discussion with the woman of the potential benefits and risks of this approach and the lack of data to address its efficacy and safety.

Antiretroviral Drug Resistance and Resistance Testing in Pregnancy

The development of antiretroviral drug resistance is one of the major factors leading to therapy failure in HIV-1-infected persons. Resistant viral variants emerge under selective pressure, especially with incompletely suppressive regimens, because of the inherent mutation-prone process of reverse transcription with viral replication. The administration of combination antiretroviral therapy with maximal suppression of viral replication to undetectable levels limits the development of antiretroviral resistance in both pregnant and nonpregnant persons. Some have raised concern that using non-highly active antiretroviral regimens, such as ZDV monotherapy, for prophylaxis against perinatal transmission could result in the development of resistance, which, in turn, could influence perinatal transmission and limit future maternal therapeutic options. Additionally, the general implications of antiretroviral resistance for maternal, fetal, and newborn health are of increasing interest as more HIV-1-infected women enter pregnancy with prior exposure to antiretroviral drugs.

The prevalence of antiretroviral drug resistance mutations in virus from newly infected, therapy-naive persons has varied by geographic area and the type of assay used (genotypic versus phenotypic) (114,123–126). In surveys from the United States and Europe, rates of primary resistance mutations in

the reverse transcriptase gene were >10% in the majority of studies and ranged as high as 23%. Primary resistance mutations in the protease gene ranged from 1% to 16%, and secondary mutations and polymorphisms of the protease gene were very common. The presence of high-level phenotypic resistance (≥ 10 -fold increase in 50% inhibitory concentration [IC_{50}]) was uncommon but tended to occur among isolates with genotypic resistance. Lower level resistance (2.5- to 10-fold decrease in susceptibility) was more common and tended to occur in the absence of genotypic mutations known to confer resistance.

The prevalence of resistance mutations during pregnancy also varies depending on the characteristics of the population studied. No high-level resistance to ZDV was detected at baseline among a subset of women enrolled in PACTG 076, all of whom had CD4⁺ counts >200 cells/mL and had received no or only limited prior ZDV therapy (108). Conversely, among women receiving ZDV for maternal health indications before 1994 in the Women and Infants Transmission Study (WITS), any ZDV resistance mutation was detected in 35 (25%) of 142 isolates, and high-level ZDV resistance was detected in 14 (10%) isolates (127). Codon 215 mutations, associated with high-level ZDV resistance, were detected in isolates from 9.6% of 62 consecutive women in the Swiss HIV-1 in Pregnancy Study (115). Similarly, in New York, codon 215 mutations were detected in no isolates from 33 women who delivered before 1997 and three (9.7%) from 31 women who delivered from 1997 to 1999; mutations were detected only among women with previous ZDV exposure (128). Among 220 pregnant women with prior ZDV exposure who were enrolled in the Perinatal AIDS Collaborative Transmission Study, virus with primary mutations conferring resistance to nucleoside analog drugs was observed in 17.7%, and primary or secondary resistance mutations in 22%; none of the women had virus containing primary nonnucleoside resistance mutations, 2.3% had secondary nonnucleoside resistance mutations, and 0.5% had virus with a primary mutation conferring resistance to protease inhibitors (117). In all these studies, women evaluated for resistance mutations were a subset of the larger studies, chosen because of detectable HIV-1 RNA levels with amplifiable virus and often because of clinical findings suggesting an increased risk of resistance. Thus, the rate of resistance mutations in the entire population is likely to be much lower than in the subsets.

The detection of ZDV or other resistance mutations was not associated with an increased risk of perinatal transmission in the PACTG 076, PACTG 185, Swiss cohort, or PACTS studies (108,115,117,129). In the WITS substudy, detection of ZDV resistance was not significantly associated with

transmission on univariate analysis, but when adjusted for duration of ruptured membranes and total lymphocyte count, resistance mutations conferred an increased risk of transmission (127). Women in this cohort were receiving ZDV during pregnancy for their own health (mean CD4⁺ count at delivery 315 cells/mL), usually without intravenous ZDV during labor or ZDV for the infants. Factors associated with resistance at delivery included ZDV use before pregnancy, higher log HIV-1 RNA, and lower CD4⁺ count. Women with characteristics similar to those in the WITS substudy should be advised to take highly active antiretroviral therapy for their own health and for prevention of perinatal transmission. Although perinatal transmission of resistant virus has been reported (113,130), it appears to be unusual, and it is not clear that the presence of mutations increases the risk of transmission. In the WITS substudy, when a transmitting mother had a mixed viral population of wild-type and low-level resistant virus, only the wild-type virus was found in the infant, suggesting that virus with low-level ZDV resistance may be less transmissible (116).

Another concern is the potential for resistance developing in the mother during prophylaxis against perinatal transmission, which may then influence future therapy options. In some combination antiretroviral clinical trials, patients with previous ZDV therapy experienced less benefit from combination therapy than those who had never received prior antiretroviral therapy (12,131). However, in these studies the median duration of prior ZDV use was 12–20 months, and enrolled patients had more advanced disease and lower CD4⁺ counts than did the population of women enrolled in PACTG 076 or those for whom initiation of therapy would be considered optional. In one study, patients with <12 months of ZDV responded as favorably to combination therapy as those without prior ZDV therapy (131). In PACTG 076, the median duration of ZDV therapy was 11 weeks; the maximal duration of ZDV (begun at 14 weeks' gestation) would be 6.5 months for a full-term pregnancy. Additionally, the development of resistance should be minimized by providing highly active antiretroviral regimens for all women during pregnancy to suppress viral replication to undetectable levels. However, women with low maternal HIV-1 RNA levels may choose the PACTG 076 ZDV regimen to minimize exposure of the fetus to antiretroviral drugs, provided their plasma HIV-1 RNA remains very low or undetectable. Among a subset of women from PACTG 076 (transmitters in the ZDV group, a random selection of nontransmitters in the ZDV group, and women with a history of prior ZDV therapy), no high-level resistance mutations were detected at baseline or delivery, and a low-level resistance mutation developed between baseline and

delivery in virus from one (2.6%) of 39 women (108). Data from an analysis of PACTG 288, a follow-up study of the women enrolled in PACTG 076 who were monitored for a median of >4 years postpartum, indicate no substantial differences in CD4⁺ count, HIV-1 RNA copy number, development of ZDV resistance, or time to progression to AIDS or death among women who received ZDV compared with those who received placebo (132).

Rapid development of resistance to 3TC has been reported among persons receiving dual nucleoside therapy without other agents. In a small study, the M184V 3TC resistance mutation was detectable by delivery in four (80%) of five women treated with ZDV-3TC during pregnancy (133). In a French cohort in which 3TC was added at 32 weeks' gestation to the PACTG 076 ZDV regimen, among 132 samples tested from 6 weeks postpartum, the M184V mutation was detected in 52 (39%); the prevalence of this mutation, before receipt of 3TC, was only 2% (27). ZDV resistance mutations included T215Y/F in nine (7%), M41L in nine (7%), and K70R in 14 (11%). In multivariate analyses, factors associated with detection of the M184V mutation after delivery included lower CD4⁺ count, higher HIV-1 RNA levels, and longer duration of 3TC therapy. Thus, dual nucleoside therapy is not recommended for treatment of nonpregnant persons with HIV-1 infection or pregnant women who fulfill criteria for initiation of antiretroviral therapy for their own health. These 3TC resistance mutations have also been noted in clinical trials of three drug combinations including 3TC (134,135). In selected circumstances, dual nucleoside therapy may be considered for pregnant women who are receiving antiretroviral agents for perinatal prophylaxis only. The potential benefits and risks of this approach have not been well studied, and concerns exist about the potential for inadequate viral suppression and rapid development of resistance with use of dual nucleoside treatment.

Selection of nevirapine-resistant virus has also been detected at 6 weeks postpartum in women receiving a single dose of nevirapine during labor. In HIVNET 012, in which antiretroviral-naïve Ugandan women received a single dose of nevirapine during labor to prevent perinatal HIV-1 transmission, genotypic mutations associated with nevirapine resistance were detected at 6 weeks postpartum in samples from 21 (19%) of 111 women with detectable viral replication who received nevirapine (136). The rate of resistance was similar among mothers whose children were or were not infected. Development of resistance was associated with significantly higher baseline viral loads and lower CD4⁺ counts. Samples taken 12–24 months after delivery from a subset of these women no longer had detectable nevirapine resistance, suggesting that this regimen might be effective for perinatal

prophylaxis in subsequent pregnancies. Implications concerning the transient development of detectable nevirapine genotypic resistance mutations from single-dose nevirapine for future maternal therapeutic options are unclear.

Further data are needed to assess the frequency of development of resistance with single-dose intrapartum nevirapine used alone versus with other agents such as ZDV in women who have not received antenatal treatment. In PACTG 316, in which single-dose nevirapine administered during labor and to the newborn was added to the woman's existing antiretroviral regimen, newly detectable nevirapine-resistance mutations were detected at 6 weeks postpartum in 14 (15%) of 95 women who received single-dose intrapartum nevirapine and had detectable HIV-1 RNA at delivery (137). The risk for development of a new nevirapine resistance mutation did not correlate with CD4⁺ count at delivery, HIV-1 RNA copy number, or type of antenatal antiretroviral treatment (resistance occurred in women receiving highly active antiretroviral therapy as well as ZDV monotherapy). Given lack of further reduction of transmission with nevirapine added to an established regimen (69) and the potential development of resistance, addition of nevirapine during labor for women already receiving antiretroviral therapy is not recommended.

The International AIDS Society-USA Panel and EuroGuidelines Group for HIV-1 Resistance recommend that all pregnant women with detectable HIV-1 RNA levels undergo resistance testing, even if they are antiretroviral naive, to try to maximize the response to antiretroviral drugs in pregnancy, although data to support an improved maternal outcome or reduced risk of perinatal transmission with routine resistance testing are not available (138,139). Until further data are available, resistance testing for HIV-1-infected pregnant women should be done for the same indications as for nonpregnant persons:

- those with acute infection;
- those who have virologic failure with persistently detectable HIV-1 RNA levels while receiving antenatal therapy, or suboptimal viral suppression after initiation of antiretroviral therapy; or
- those with a high likelihood of having resistant virus, based on community prevalence of resistant virus, known drug resistance in the woman's sex partner, or other source of infection.

The optimal prophylactic regimen for newborns of women with ZDV resistance is unknown. Therefore, antiretroviral prophylaxis of the infant born to a woman with known or suspected ZDV-resistant HIV-1 should be determined in consultation with pediatric infectious disease specialists.

Recommendations related to antiretroviral drug resistance and drug resistance testing for pregnant women with HIV-1 infection are listed here (Box 2).

Perinatal HIV-1 Transmission and Mode of Delivery

Transmission and Mode of Delivery

Optimal medical management during pregnancy should include antiretroviral therapy to suppress plasma HIV-1 RNA to undetectable levels. Labor and delivery management of HIV-1-infected pregnant women should focus on minimizing the risk for both perinatal transmission of HIV-1 and the potential for maternal and neonatal complications.

Several studies done before viral load testing and combination antiretroviral therapy became a routine part of clinical practice consistently showed that cesarean delivery (elective or scheduled) performed before onset of labor and rupture of membranes was associated with a significant decrease in perinatal HIV-1 transmission compared with other types of delivery, with reductions ranging from 55% to 80%. Data regarding transmission rates according to receipt of ZDV have been summarized (Table 4) (140,141).

The observational data comprised individual patient information from 15 prospective cohort studies, including more than 7,800 mother-child pairs, analyzed in a meta-analysis (140). In this meta-analysis, the rate of perinatal HIV-1 transmission among women undergoing elective cesarean delivery was significantly lower than that among similar women having either nonelective cesarean or vaginal delivery, regardless of whether they received ZDV. In an international randomized trial of mode of delivery, transmission was 1.8% among women randomized to elective cesarean delivery, many of whom received ZDV (141). Although the reduction in transmission after elective cesarean section versus vaginal delivery among women receiving ZDV in the randomized trial was similar to that seen in untreated women, this was not statistically significant. Additionally, in both studies, nonelective cesarean delivery (performed after onset of labor or rupture of membranes) was not associated with a significant decrease in transmission compared with vaginal delivery. The American College of Obstetricians and Gynecologists' (ACOG) Committee on Obstetric Practice, after reviewing these data, has issued a Committee Opinion concerning route of delivery recommending consideration of scheduled cesarean delivery for HIV-1-infected pregnant women with HIV-1 RNA levels >1,000 copies/ml near the time of delivery (142).

BOX 2. Recommendations related to antiretroviral drug resistance and drug resistance testing for pregnant women with human immunodeficiency virus type 1 (HIV-1) infection

- All pregnant women should be offered highly active antiretroviral therapy to maximally suppress viral replication, reduce the risk of perinatal transmission, and minimize the risk of development of resistant virus.
- For women for whom combination antiretroviral therapy would be considered optional (HIV-1 RNA <1,000 copies/ml) and who wish to restrict their exposure to antiretroviral drugs during pregnancy, monotherapy with the three-part zidovudine (ZDV) prophylaxis regimen (or in selected circumstances, dual nucleosides) should be offered. In these circumstances, the development of resistance should be minimized by limited viral replication (assuming HIV-1 RNA levels remain low) and the time-limited exposure to ZDV. Monotherapy with ZDV does not suppress HIV-1 replication to undetectable levels in most cases; theoretically, such therapy might select for ZDV-resistant viral variants, potentially limiting future treatment options. These considerations should be discussed with the pregnant woman.
- Recommendations for resistance testing for HIV-1-infected pregnant women are the same as for nonpregnant patients: acute HIV-1 infection, virologic failure, suboptimal viral suppression after initiation of antiretroviral therapy, or high likelihood of exposure to resistant virus based on community prevalence or source characteristics.
- Women who have a history of presumed or documented ZDV resistance and are receiving antiretroviral regimens that do not include ZDV for their own health should still receive intravenous ZDV intrapartum and oral ZDV for their infants according to the PACTG 076 protocol whenever possible. A key mechanism by which ZDV reduces perinatal transmission is likely through pre- and postexposure prophylaxis of the infant, which may be less dependent on drug sensitivity than is reduction of viral replication. However, these women are not good candidates for ZDV alone.
- Optimal antiretroviral prophylaxis of the infant born to a woman with HIV-1 known to be resistant to ZDV or other agents should be determined in consultation with pediatric infectious disease specialists, taking into account resistance patterns, available drug formulations, and infant pharmacokinetic data, when available.
- If women receiving combination therapy require temporary discontinuation for any reason during pregnancy, all drugs should be stopped and reintroduced simultaneously to reduce the potential for emergence of resistance.
- Optimal adherence to antiretroviral medications is a key part of the strategy to reduce the development of resistance.
- Because the prevalence of drug-resistant virus is an evolving phenomenon, surveillance is needed to monitor the prevalence of drug-resistant virus in pregnant women over time and the risk of transmission of resistant viral strains.

TABLE 4. Rate of perinatal HIV-1 transmission according to receipt of zidovudine (ZDV) during pregnancy and mode of delivery

Study design	Therapy	Transmission rate				Odds ratio (95% CI)*
		Elective cesarean section (%)	Other modes (%)			
Observational data [†]	No ZDV	58/559 (10.4)	1,021/5,385 (19)		0.49 (0.4–0.7)	
	ZDV	4/196 (2)	92/1,255 (7.3)		0.26 (0.07–0.7)	
Randomized trial [§]	No ZDV	2/51 (4)	16/82 (20)		0.20 (0–0.8)	
	ZDV	1/119 (1)	5/117 (4)		0.20 (0–1.7)	

* Confidence interval.

[†] **Source:** The International Perinatal HIV Group. The mode of delivery and risk of vertical transmission of human immunodeficiency virus type 1. A meta-analysis of 15 prospective cohort studies. *N Engl J Med* 1999;340:977–87.

[§] **Source:** The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. *Lancet* 1999;353:1035–9.

Transmission, Viral Load, and Combination Antiretroviral Therapy

The studies described previously report data from women not receiving combination antiretroviral therapy or undergoing routine viral load testing, and they do not differentiate in utero from intrapartum transmission. Whether cesarean delivery offers any benefit to the infants of women receiving highly active combination antiretroviral regimens who have low or undetectable maternal HIV-1 RNA levels is unknown. Studies evaluating vertical transmission rates according to maternal HIV-1 RNA copy number have used a variety of

assays with different lower limits of detection, and transmission has been reported even when maternal HIV-1 RNA levels were below assay quantification (52,75,143,144). There does not appear to be a threshold of HIV-1 RNA levels below which lack of transmission can be assured. Nevertheless, on the basis of the upper limits of the 95% confidence interval reported for transmission from women who have undetectable viral load in late pregnancy, the highest rates of transmission among such women are similar to the observed rates of vertical transmission among women who receive ZDV and undergo elective cesarean delivery. Transmission occurred only once in four studies involving 29, 32, 107, and 198 women with undetectable viral load (≤ 500 copies/mL) late in pregnancy, 95% of whom were receiving at least ZDV and almost half receiving two or more antiretroviral agents (78,79,145,146). Scheduled cesarean delivery is unlikely to further reduce this low transmission rate among treated women with undetectable viral loads, nor would it prevent in utero transmission. Given the variability in quantification of HIV-1 RNA levels at low copy numbers, the variety of lower limits of quantification of the tests, and the similarly low levels of perinatal transmission of HIV-1 at levels $< 1,000$ copies/mL, ACOG has chosen 1,000 copies/mL as the threshold above which to recommend scheduled cesarean delivery as an adjunct for prevention of transmission (142).

Similarly low vertical transmission rates have been observed among limited numbers of women receiving combination antiretroviral therapy during pregnancy. Three limited studies have shown transmission among one (6.7%) of 15 and none of 30 and 24 women receiving two or more antiretroviral drugs in combination during pregnancy (21,88,133). Additional studies in abstract form reported no transmission among 153 women receiving highly active combination antiretroviral therapy, whereas others have reported transmission rates of 1% (2/187) and 5.8% (3/52) among women receiving triple therapy including a protease inhibitor (147–149). Whether the low transmission rates with combination therapy are due to reduction in HIV-1 RNA to very low or undetectable levels or to some other mechanism (e.g., transplacental drug passage providing preexposure prophylaxis to the infant) is unknown because HIV-1 RNA levels were not reported. Thus, current data are insufficient to adequately assess whether the impact of combination antiretroviral therapy on vertical transmission is independent from its effect on viral load. Therefore, scheduled cesarean delivery is recommended for women with HIV-1 RNA $> 1,000$ copies/mL near the time delivery, regardless of the type of antiretroviral therapy the woman is receiving.

Maternal Risks by Mode of Delivery

Among women not infected with HIV-1, maternal morbidity and mortality are greater after cesarean than after vaginal delivery. Complications, especially postpartum infections, are approximately five to seven times more common after cesarean section performed after labor or membrane rupture compared with vaginal delivery (150,151). Complications after scheduled cesarean delivery are more common than with vaginal delivery but less than with urgent cesarean delivery (152–156). Factors that increase the risk of postoperative complications include low socioeconomic status, genital infections, obesity or malnutrition, smoking, and prolonged labor or membrane rupture.

In the European mode of delivery randomized trial among HIV-1–infected pregnant women, no major complications occurred in either the cesarean or vaginal delivery group (141). However, postpartum fever occurred in two (1.1%) of 183 women who delivered vaginally and 15 (6.7%) of 225 who delivered by cesarean section ($p = 0.002$). Substantial postpartum bleeding and anemia occurred at similar rates in the two groups. Among the 497 women enrolled in PACTG 185, only endometritis, wound infection, and pneumonia were increased among women delivered by scheduled or urgent cesarean section, compared with vaginal delivery (157). Complication rates were within the range previously reported for similar general obstetric populations. Finally, an analysis of nearly 1,200 women enrolled in WITS demonstrated increased rate of postpartum fever without documented source of infection among women undergoing elective cesarean delivery compared with spontaneous vaginal delivery, but hemorrhage, severe anemia, endometritis or urinary tract infections were not increased (158). In the latter two studies, cesarean deliveries before onset of labor and ruptured membranes were done for obstetric indications such as previous cesarean section or severe preeclampsia and not for prevention of HIV-1 transmission, possibly resulting in higher complication rates than might be observed for scheduled cesarean section performed solely to reduce perinatal transmission.

In a more recent study including a cohort of HIV-1–infected women with a larger proportion of women undergoing scheduled cesarean delivery specifically for prevention of HIV-1 transmission, fever was increased after cesarean compared with vaginal delivery (159). In a multivariate analysis adjusted for maternal CD4⁺ count and antepartum hemorrhage, the relative risk of any postpartum complication was 1.85 (95% CI = 1.00–3.39) after elective cesarean delivery and 4.17 (95% CI = 2.32–7.49) after emergency cesarean delivery, compared with that for women delivering vaginally.

Febrile morbidity was increased among women with low CD4⁺ counts, which was consistent with findings in previous studies (160,161).

Several case-control studies and a cohort study have reported complication rates among HIV-1–infected versus uninfected women undergoing cesarean delivery, usually on an urgent rather than scheduled basis (160–166). All but one study detected an increase in postpartum fever or antibiotic use among the HIV-1–infected women, although increases in specific infections such as endometritis, wound infection, or pneumonia were found in some but not all studies. Complication rates were inversely related to CD4⁺ count or clinical stage of HIV-1 disease. In the one study in which it was evaluated, antiretroviral therapy with ZDV was associated with a decreased rate of infectious complications, although this was not statistically significant (odds ratio = 3.1, 95% CI = 0.07–1.3) (165).

In summary, data indicate that cesarean delivery is associated with a slightly greater risk of complications among HIV-1–infected women than observed among uninfected women, with the difference most notable among women with more advanced disease. Scheduled cesarean delivery for prevention of HIV-1 transmission poses a risk greater than that of vaginal delivery and less than that of urgent or emergent cesarean section. Complication rates in most studies were within the range reported in populations of HIV-1–uninfected women with similar risk factors and were not of sufficient frequency or severity to outweigh the potential benefit of reduced transmission among women at heightened risk of transmission. HIV-1–infected women should be counseled regarding the increased risks associated with cesarean delivery as well as the potential benefits based on their HIV-1 RNA levels and current antiretroviral therapy.

Timing of Scheduled Cesarean Delivery

If the decision is made to perform a scheduled cesarean delivery to prevent HIV-1 transmission, ACOG recommends that it be done at 38 weeks' gestation, determined by using clinical and first or second trimester ultrasonographic estimates of gestational age and avoiding amniocentesis (142). For HIV-1–uninfected women, ACOG guidelines for scheduled cesarean delivery without confirmation of fetal lung maturity advise waiting until 39 completed weeks or the onset of labor to reduce the chance of complications in the neonate (167). Cesarean delivery at 38 versus 39 weeks entails a small absolute but substantially increased risk of development of infant respiratory distress requiring mechanical ventilation (168,169). This increased risk must be balanced against the potential risk for labor or membrane rupture before the

woman would reach 39 weeks of gestation. Women should be informed of the potential risks and benefits to themselves and their infants in choosing the timing and mode of delivery.

Intrapartum Management

For a scheduled cesarean delivery, intravenous ZDV should begin 3 hours before surgery, according to standard dosing recommendations (2). Other antiretroviral medications taken during pregnancy should not be interrupted near the time of delivery, regardless of route of delivery. Because maternal infectious morbidity is potentially increased, clinicians may opt to give perioperative antimicrobial prophylaxis. No controlled studies have evaluated the efficacy of antimicrobial prophylaxis specifically for HIV-1–infected women undergoing scheduled operative delivery (170).

Unanswered questions remain regarding the most appropriate management of labor in cases in which vaginal delivery is attempted. Increasing duration of membrane rupture has been demonstrated consistently to be a risk factor for perinatal transmission among women not receiving any antiretroviral therapy (93,143,171,172). Among women receiving ZDV, some studies have shown an increased risk of transmission with ruptured membranes for 4 or more hours before delivery (9,79), but others have not (78,145). The additive risk and the critical time of ruptured membranes for perinatal HIV-1 transmission in women with low viral loads and/or receiving combination antiretroviral therapy are unknown. Obstetric procedures increasing the risk of fetal exposure to maternal blood, such as amniocentesis and invasive monitoring, have been implicated in increasing vertical transmission rates by some but not all investigators (78,173–175). If labor is progressing and membranes are intact, artificial rupture of membranes or invasive monitoring should be avoided. These procedures should be considered only when obstetrically indicated and the length of time for ruptured membranes or monitoring is anticipated to be short. If spontaneous rupture of membranes occurs before or early during the course of labor, interventions to decrease the interval to delivery, such as administration of pitocin, might be considered.

Summary

Considerations related to counseling of the HIV-1–infected pregnant woman regarding risks for vertical transmission of HIV-1 to the fetus/neonate and to the obstetric care of such women include the following:

- Efforts to maximize the health of the pregnant woman, including the provision of highly active combination antiretroviral therapy, can be expected to correlate

with both reduction in viral load and low rates of vertical transmission. At a minimum for the reduction of perinatal HIV-1 transmission, ZDV prophylaxis according to the PACTG 076 regimen is recommended unless the woman is intolerant of ZDV.

- Plasma HIV-1 RNA levels should be monitored during pregnancy according to the guidelines for management of HIV-1–infected adults. The most recently determined viral load value should be used when counseling a woman regarding mode of delivery.
- Perinatal HIV-1 transmission is reduced by scheduled cesarean section among women with unknown HIV-1 RNA levels who are not receiving antiretroviral therapy or receiving ZDV for prophylaxis of perinatal transmission. Plasma HIV-1 RNA levels were not available in these studies to assess the potential benefit among women with low plasma HIV-1 RNA levels.
- Women with HIV-1 RNA levels >1,000 copies/mL should be counseled regarding the benefit of scheduled cesarean delivery in reducing the risk of vertical transmission.
- Data are insufficient to evaluate the potential benefit of cesarean section for neonates of antiretroviral-treated women with plasma HIV-1 RNA levels below 1,000 copies/mL. Given the low rate of transmission among this group, it is unlikely that scheduled cesarean section would confer additional benefit in reduction of transmission.
- Management of women originally scheduled for cesarean delivery who present with ruptured membranes must be individualized based on duration of rupture, progress of labor, plasma HIV-1 RNA level, current antiretroviral therapy, and other clinical factors.
- Women should be informed of the risks associated with cesarean delivery, and these risks to the woman should be balanced with potential benefits expected for the neonate.
- Women should be counseled regarding the limitations of the current data. The woman's autonomy to make an informed decision regarding route of delivery should be respected and honored.

Clinical Situations

The following recommendations are based on various hypothetical situations that may be encountered in clinical practice (Box 3), with relevant considerations highlighted in the subsequent discussion sections. These recommendations are only guidelines, and flexibility should be exercised according to the patient's individual circumstances.

1. HIV-1–infected women presenting in late pregnancy (after approximately 36 weeks of gestation), known to be HIV-1 infected but not receiving antiretroviral therapy, and whose results for HIV-1 RNA level and lymphocyte subsets are pending but unlikely to be available before delivery.

Recommendation. Therapy options should be discussed in detail. Antiretroviral therapy, including at least the PACTG 076 ZDV regimen, should be initiated. In counseling, the woman should be informed that scheduled cesarean section is likely to reduce the risk of transmission to her infant. She should also be informed of the increased risks to her of cesarean delivery, including increased rates of postoperative infection, anesthesia risks, and other surgical risks. If cesarean delivery is chosen, the procedure should be scheduled at 38 weeks of gestation, based on the best available clinical information. When scheduled cesarean section is performed, the woman should receive continuous intravenous ZDV infusion beginning 3 hours before surgery, and her infant should receive 6 weeks of ZDV therapy after birth. Options for continuing or initiating combination antiretroviral therapy after delivery should be discussed with the woman as soon as her viral load and lymphocyte subset results are available.

Discussion. Women in these circumstances are similar to women enrolled in the European randomized trial and those evaluated in the meta-analysis (140,141). In both studies, the population not receiving antiretroviral therapy was shown to have a significant reduction in transmission with cesarean section done before labor or membrane rupture. HIV-1 RNA levels were not available in these studies. Without current therapy, the HIV-1 RNA level are unlikely to be <1,000 copies/mL. Even if combination therapy were begun immediately, reduction in plasma HIV-1 RNA to undetectable levels usually takes several weeks, depending on the starting RNA level. ZDV monotherapy could be begun, with subsequent antiretroviral therapy decisions made after delivery based on the HIV-1 RNA level, CD4⁺ count, and the woman's preference regarding initiation of long-term combination therapy. Scheduled cesarean section and the three-part PACTG 076 ZDV regimen offer the best chance of preventing perinatal HIV-1 transmission in this setting.

BOX 3. Clinical situations and recommendations regarding mode of delivery to reduce perinatal human immunodeficiency virus type 1 (HIV-1) transmission**1. HIV-1–infected women presenting in late pregnancy (after approximately 36 weeks of gestation), known to be HIV-1 infected but not receiving antiretroviral therapy, and whose results for HIV RNA level and lymphocyte subsets are pending but unlikely to be available before delivery**

- Therapy options should be discussed in detail. Antiretroviral therapy, including at least the PACTG 076 zidovudine (ZDV) regimen, should be initiated. In counseling, the woman should be informed that scheduled cesarean section is likely to reduce the risk of transmission to her infant. She should also be informed of the increased risks to her of cesarean delivery, including increased rates of postoperative infection, anesthesia risks, and other surgical risks.
- If cesarean delivery is chosen, the procedure should be scheduled at 38 weeks of gestation, based on the best available clinical information. When scheduled cesarean section is performed, the woman should receive continuous intravenous ZDV infusion beginning 3 hours before surgery, and her infant should receive 6 weeks of ZDV therapy after birth. Options for continuing or initiating combination antiretroviral therapy after delivery should be discussed with the woman as soon as her viral load and lymphocyte subset results are available.

2. HIV-1–infected women who began prenatal care early in the third trimester, are receiving highly active combination antiretroviral therapy, and have an initial virologic response but have HIV-1 RNA levels that remain substantially over 1,000 copies/mL at 36 weeks of gestation

- The current combination antiretroviral regimen should be continued since the HIV-1 RNA level is dropping appropriately. The woman should be informed that although her HIV-1 RNA level is responding to the antiretroviral therapy, it is not likely to decline to <1,000 copies/mL before delivery. Therefore, scheduled cesarean section may provide additional benefit in preventing intrapartum transmission of HIV-1. She should also be informed of the increased risks to her of cesarean delivery, including increased rates of postoperative infection, anesthesia risks, and surgical risks.

- If she chooses scheduled cesarean delivery, it should be performed at 38 weeks' gestation, and intravenous ZDV should be begun at least 3 hours before surgery. Other antiretroviral medications should be continued on schedule as much as possible before and after surgery. The infant should receive oral ZDV for 6 weeks after birth. The importance of adhering to therapy after delivery for her own health should be emphasized.

3. HIV-1–infected women receiving highly active combination antiretroviral therapy who have an undetectable HIV-1 RNA level at 36 weeks of gestation

- The woman should be informed that her risk of perinatal transmission of HIV-1 with a persistently undetectable HIV-1 RNA level is low, probably 2% or less, even with vaginal delivery. No information is currently available on which to determine whether performing a scheduled cesarean section will lower her risk further.
- Cesarean delivery has an increased risk of complications for the woman compared with vaginal delivery, and these risks must be balanced against the uncertain benefit of cesarean delivery in this case.

4. HIV-1–infected women who have elected scheduled cesarean delivery but present in early labor or shortly after rupture of membranes

- Intravenous ZDV should be started immediately because the woman is in labor or has ruptured membranes.
- If labor is progressing rapidly, the woman should be allowed to deliver vaginally. If cervical dilatation is minimal and a long period of labor is anticipated, some clinicians may administer the loading dose of intravenous ZDV and proceed with cesarean section to minimize the duration of membrane rupture and avoid vaginal delivery. Alternatively, the clinicians might begin pitocin augmentation to enhance contractions and potentially expedite delivery.
- If the woman is allowed to labor, scalp electrodes and other invasive monitoring and operative delivery should be avoided if possible. The infant should be treated with 6 weeks of ZDV therapy after birth.

2. HIV-1–infected women who began prenatal care early in the third trimester, are receiving highly active combination antiretroviral therapy, and have an initial virologic response but have HIV-1 RNA levels that remain substantially over 1,000 copies/mL at 36 weeks of gestation.

Recommendation. The current combination antiretroviral regimen should be continued because the HIV-1 RNA level is declining appropriately. The woman should be informed that although her HIV-1 RNA level is responding to the antiretroviral therapy, it is unlikely that it will reach <1,000 copies/mL before delivery. Therefore, scheduled cesarean delivery may provide additional benefit in preventing intrapartum transmission of HIV-1. She should also be informed of the increased risks to her of cesarean delivery, including increased rates of postoperative infection, anesthesia risks, and surgical risks. If she chooses scheduled cesarean section, it should be performed at 38 weeks' gestation, and intravenous ZDV should be begun at least 3 hours before surgery. Other antiretroviral medications should be continued on schedule as much as possible before and after surgery. The infant should receive oral ZDV for 6 weeks after birth. The importance of adhering to therapy after delivery for her own health should be emphasized.

Discussion. In cohorts of women receiving ZDV therapy with low rates of scheduled cesarean delivery, current data indicate that the rate of vertical transmission of HIV-1 is 1%–12% (mean 5.7%) when HIV-1 RNA levels near delivery are 1,000–10,000 copies/mL, and is 9%–29% (mean 12.6%) when HIV-1 RNA levels are >10,000 copies/mL (52,62,74,78,79,145). Although current combination antiretroviral therapy regimens may be expected to suppress HIV-1 RNA to undetectable levels with continued use, these levels are likely to still be detectable within the period of expected delivery. Scheduled cesarean delivery might further reduce the rate of intrapartum HIV-1 transmission and should be recommended to women with HIV-1 RNA levels >1,000 copies/mL. Although several studies have suggested low levels of vertical transmission of HIV-1 among pregnant women receiving combination antiretroviral therapy, each has included limited numbers of women and has not adjusted for maternal HIV-1 RNA levels (61,88,133,148). Thus, it is not clear if the impact on transmission is related to the lowering of maternal plasma HIV-1 RNA levels, preexposure prophylaxis of the infant, other mechanisms, or some combination. Until further data are available, women with HIV-1 RNA levels >1,000 copies/mL should be offered scheduled cesarean delivery regardless of maternal therapy.

Regardless of mode of delivery, the woman should receive the PACTG 076 intravenous ZDV regimen intrapartum, and the infant should receive ZDV for 6 weeks after birth. Other maternal drugs should be continued on schedule as much as possible to provide maximal effect and minimize the chance of development of viral resistance. Oral medications may be continued preoperatively with sips of water. Medications requiring food ingestion for absorption could be taken with liquid dietary supplements, but consultation with the attending anesthesiologist should be obtained before administering in the preoperative period. If maternal antiretroviral therapy must be interrupted temporarily in the peripartum period, all drugs (except for intrapartum intravenous ZDV) should be stopped and reinstated simultaneously to minimize the chance of resistance developing.

Women with CD4⁺ counts <350 cells/mL or HIV-1 RNA levels >55,000 copies/mL before initiation of combination therapy during pregnancy are most likely to benefit from continued antiretroviral therapy after delivery (14). Discussion regarding plans for antiretroviral therapy after delivery should be initiated during pregnancy. If the woman elects to continue therapy after delivery, the importance of continued adherence despite the increased responsibilities of newborn care should be emphasized and any support available for the woman should be provided.

3. HIV-1–infected women receiving highly active combination antiretroviral therapy who have an undetectable HIV-1 RNA level at 36 weeks of gestation.

Recommendation. The woman should be informed that her risk of perinatal transmission of HIV-1 with a persistently undetectable HIV-1 RNA level is low, probably 2% or less, even with vaginal delivery. No information is currently available on which to determine whether performing a scheduled cesarean delivery will lower her risk further. Cesarean delivery has an increased risk of complications for the woman compared with vaginal delivery, and these risks must be balanced against the uncertain benefit of cesarean delivery in this case.

Discussion. Scheduled cesarean delivery has been beneficial for women either receiving no antiretroviral therapy or receiving ZDV monotherapy, with rates of transmission of HIV-1 of approximately 1%–2% (140,141). Maternal HIV-1 RNA levels were not evaluated in these studies. Similar rates of transmission have been reported among women receiving antiretroviral therapy, with HIV-1 RNA levels undetectable near delivery (78,79,146). No data are available evaluating transmission rates by mode of delivery among women with undetectable HIV-1 RNA levels. Although a benefit of cesarean delivery in reducing transmission may be present, it would

be of small magnitude given the low risk of transmission with vaginal delivery among women with HIV-1 RNA levels <1,000 copies/mL who are receiving maternal antiretroviral therapy. Any benefit must be weighed against the known increased risks to the woman with cesarean section compared with vaginal delivery, i.e., a severalfold increased risk of postpartum infections, including uterine infections and pneumonia, anesthesia risks, and surgical complications. However, given no data to indicate lack of benefit, if a woman chooses a scheduled cesarean delivery, her decision should be respected and cesarean delivery scheduled.

If vaginal delivery is chosen, the duration of ruptured membranes should be minimized because the transmission rate has been shown to increase with longer duration of membrane rupture among predominantly untreated women (143,171,172) and among ZDV-treated women in some (9,79) but not all studies (78,145). Fetal scalp electrodes and operative delivery with forceps or the vacuum extractor may increase the risk of transmission and should be avoided (173, 174). Intravenous ZDV should be given during labor, and maternal drugs should be continued on schedule as much as possible to provide maximal effect and minimize the chance of development of viral resistance, and the infant should be treated with ZDV for 6 weeks after birth.

4. HIV-1–Infected women who have elected scheduled cesarean section but present in early labor or shortly after rupture of membranes.

Recommendation. Intravenous ZDV should be started immediately since the woman is in labor or has ruptured membranes. If labor is progressing rapidly, the woman should be allowed to deliver vaginally. If cervical dilatation is minimal and a long period of labor is anticipated, the clinician may administer the loading dose of intravenous ZDV and proceed with cesarean section to minimize the duration of membrane rupture and avoid vaginal delivery. Alternatively, the clinician might begin pitocin augmentation to enhance contractions and potentially expedite delivery. If the woman is allowed to labor, scalp electrodes and other invasive monitoring and operative delivery should be avoided if possible. The infant should be treated with 6 weeks of ZDV therapy after birth.

Discussion. No data are available to address the question of whether performing cesarean section soon after membrane rupture to shorten labor and avoid vaginal delivery decreases the risk of vertical transmission of HIV-1. Most studies have shown the risk of transmission with cesarean section done after labor and membrane rupture for obstetric indications to be similar to that with vaginal delivery, although the duration of ruptured membranes in these women was often longer than

4 hours (141,176). When an effect was demonstrated, the risk of transmission was twice as high among women with ruptured membranes for ≥ 4 hours before delivery compared with those with shorter duration of membrane rupture, although the risk increased continuously with increasing duration of rupture (See Situation 3).

If elective cesarean delivery had been planned and the woman presents with a short duration of ruptured membranes or labor, she should be informed that the benefit of cesarean section under these circumstances is unclear and be allowed to reassess her decision. If the woman presents after 4 hours of membrane rupture, cesarean section is less likely to affect transmission of HIV-1. The woman should be informed that the benefit of cesarean section is unclear and that her risks of perioperative infection increase with increasing duration of ruptured membranes.

If cesarean delivery is chosen, the loading dose of ZDV should be administered while preparations are made for cesarean delivery and the infusion continued until cord clamping. Prophylactic antibiotics given after cord clamping have been shown to reduce the rate of postpartum infection among women of unknown HIV-1 status undergoing cesarean section after labor or rupture of membranes and should be used routinely in this setting (170). If vaginal delivery is chosen, intravenous ZDV and other antiretroviral agents the woman is currently taking should be administered and invasive procedures such as internal monitoring avoided. Pitocin should be used as needed to expedite delivery.

Recommendations for Monitoring of Women and Their Infants

Pregnant Woman and Fetus

HIV-1 infected pregnant women should be monitored according to the same standards for monitoring HIV-1–infected persons who are not pregnant. This monitoring should include measurement of CD4⁺ counts and HIV-1 RNA levels approximately every trimester (i.e., every 3 to 4 months) to determine the need for antiretroviral therapy for maternal HIV-1 disease, whether such therapy should be altered, and whether prophylaxis against *Pneumocystis carinii* pneumonia should be initiated.

Changes in absolute CD4⁺ count during pregnancy may reflect the physiologic changes of pregnancy on hemodynamic parameters and blood volume as opposed to a long-term influence of pregnancy on CD4⁺ count; CD4⁺ percentage is likely more stable and might be a more accurate reflection of immune status during pregnancy (177,178). Long-range plans should be developed with the woman regarding continuity of

medical care and antiretroviral therapy for her own health after the birth of her infant.

Monitoring for potential complications of administration of antiretroviral agents during pregnancy should be based on what is known about the side effects of the drugs the woman is receiving. For example, routine hematologic and liver enzyme monitoring is recommended for women receiving ZDV, and women receiving protease inhibitors should be monitored for the development of hyperglycemia. Because combination antiretroviral regimens have been used less extensively during pregnancy, more intensive monitoring may be warranted for women receiving drugs other than or in addition to ZDV.

Antepartum fetal monitoring for women who receive only ZDV chemoprophylaxis should be performed as clinically indicated because data do not indicate that ZDV use in pregnancy is associated with increased risk for fetal complications. Less is known about the effect of combination antiretroviral therapy on the fetus during pregnancy. Thus, more intensive fetal monitoring should be considered for mothers receiving such therapy, including assessment of fetal anatomy with a level II ultrasound and continued assessment of fetal growth and wellbeing during the third trimester.

Neonate

A complete blood count and differential should be performed on the newborn as a baseline evaluation before administration of ZDV. Anemia has been the primary complication of the 6-week ZDV regimen in the neonate; thus, repeat measurement of hemoglobin is required at a minimum after the completion of the 6-week ZDV regimen. If abnormal, repeat measurement should be performed at age 12 weeks, by which time any ZDV-related hematologic toxicity should be resolved. Infants who have anemia at birth or who are born prematurely warrant more intensive monitoring.

Data are limited concerning potential toxicities in infants whose mothers have received combination antiretroviral therapy. More intensive monitoring of hematologic and serum chemistry measurements during the first few weeks of life is advised for these infants. However, it should be noted that the clinical relevance of lactate levels in the neonatal period to assess potential for mitochondrial toxicity has not been adequately evaluated.

To prevent *P. carinii* pneumonia, all infants born to women with HIV-1 infection should begin prophylaxis at age 6 weeks, after completion of the ZDV prophylaxis regimen (179). Monitoring and diagnostic evaluation of HIV-1–exposed infants should follow current standards of care (180). Data do not indicate any delay in HIV-1 diagnosis in infants who have received the ZDV regimen (1,181). However, the effect of

combination antiretroviral therapy in the mother or newborn on the sensitivity of infant virologic diagnostic testing is unknown. Infants with negative virologic test results during the first 6 weeks of life should have diagnostic evaluation repeated after completion of the neonatal antiretroviral prophylaxis regimen.

Postpartum Follow-Up of Women

Comprehensive care and support services are important for women with HIV-1 infection and their families. Components of comprehensive care include the following medical and supportive care services:

- Primary, obstetric, pediatric, and HIV-1 specialty care,
- Family planning services,
- Mental health services,
- Substance-abuse treatment, and
- Coordination of care through case management for the woman, her children, and other family members.

Support services include case management, child care, respite care, assistance with basic life needs (e.g., housing, food, and transportation), and legal and advocacy services. This care should begin before pregnancy and should be continued throughout pregnancy and postpartum.

Maternal medical services during the postpartum period must be coordinated between obstetric care providers and HIV-1 specialists. Continuity of antiretroviral treatment when such treatment is required for the woman's HIV-1 infection is especially critical and must be ensured. Concerns have been raised about adherence to antiretroviral regimens during the postpartum period. Women should be counseled about the fact that the physical changes of the postpartum period, as well as the stresses and demands of caring for a new baby, can make adherence more difficult and additional support may be needed to maintain good adherence to their therapeutic antiretroviral regimen during this period (182,183). The health-care provider should be vigilant for signs of depression, which may require assessment and treatment and which may interfere with adherence. Poor adherence has been shown to be associated with virologic failure, development of resistance, and decreased long-term effectiveness of antiretroviral therapy (184–189). Efforts to maintain good adherence during the postpartum period might prolong the effectiveness of therapy (14).

All women should receive comprehensive health-care services that continue after pregnancy for their own medical care and for assistance with family planning and contraception. In addition, this is a good time to review immunization status and update vaccines, assess the need for prophylaxis against opportunistic infections, and reemphasize safer sex practices.

Data from PACTG 076 and 288 do not indicate adverse effects through 4 years postpartum among women who received ZDV during pregnancy (47, 132). Women who have received only ZDV chemoprophylaxis during pregnancy should receive appropriate evaluation to determine the need for antiretroviral therapy during the postpartum period.

Long-Term Follow-Up of Infants

Data remain insufficient to address the effect that exposure to ZDV or other antiretroviral agents in utero might have on long-term risk for neoplasia or organ system toxicities in children. Data from follow-up of PACTG 076 infants through age 6 years do not indicate any differences in immunologic, neurologic, and growth parameters between infants who were exposed to the ZDV regimen and those who received placebo, and no malignancies have been seen (58,59). Continued evaluation of early and late effects of in utero antiretroviral exposure is ongoing through several mechanisms, including a long-term follow-up study in the Pediatric AIDS Clinical Trials Group (PACTG 219C), natural history studies, and HIV/AIDS surveillance conducted by state health departments and CDC. Because most of the available follow-up data relate to in utero exposure to antenatal ZDV alone and most pregnant women with HIV-1 infection currently receive combination therapy, it is critical that studies to evaluate potential adverse effects of in utero drug exposure continue to be supported.

Innovative methods are needed to provide follow-up of infants with in utero exposure to antiretroviral drugs. Information regarding such exposure should be part of the ongoing permanent medical record of the child, particularly for uninfected children. Children with in utero antiretroviral exposure who develop significant organ system abnormalities of unknown etiology, particularly of the nervous system or heart, should be evaluated for potential mitochondrial dysfunction (46). Follow-up of children with antiretroviral exposure should continue into adulthood because of the theoretical concerns regarding potential for carcinogenicity of the nucleoside analog antiretroviral drugs. Long-term follow-up should include yearly physical examinations of all children exposed to antiretroviral drugs and, for adolescent females, gynecologic evaluation with Pap smears.

HIV-1 surveillance databases from states that require HIV-1 reporting provide an opportunity to collect population-based information concerning in utero antiretroviral exposure. To the extent permitted by federal law and regulations, data from these confidential registries can be used to compare with information from birth defect and cancer registries to identify potential adverse outcomes.

Clinical Research Needs

The following clinical research needs are relevant to the United States and other developed countries. Study findings continue to evolve rapidly, and research needs and clinical practice will require continued reassessment over time. The current guidelines do not attempt to address the complex research needs or antiretroviral prophylaxis recommendations for resource-limited international settings.

Evaluation of Drug Safety and Pharmacokinetics

Many pregnant women with HIV-1 infection in the United States are receiving combination antiretroviral therapy for their own health care along with standard ZDV prophylaxis to reduce perinatal HIV-1 transmission. Additionally, recent data indicate that antenatal use of potent antiretroviral combinations capable of reducing plasma HIV-1 RNA copy number to very low or undetectable levels near the time of delivery may lower the risk of perinatal transmission to <2% (61,90). While the number of antiretroviral agents and combination regimens used for treatment of infected persons is increasing rapidly, the number of drugs evaluated in pregnant women remains limited.

Preclinical evaluations of antiretroviral drugs for potential pregnancy- and fetal-related toxicities need to be completed for all existing and new antiretroviral drugs. More data are needed regarding the safety and pharmacokinetics of antiretroviral drugs in pregnant women and their neonates, particularly when used in combination regimens. Further research is also needed on whether the effects of intensive combination treatment on viral load differ in various body compartments, such as plasma and genital tract secretions, and how this may relate to risk of perinatal transmission.

Continued careful assessment for potential short- and long-term consequences of antiretroviral drug use during pregnancy for both the woman and her child is important. Consequences of particular concern include mitochondrial dysfunction; hepatic, hematologic and other potential end-organ toxicities; development of antiretroviral drug resistance; and adverse effects on pregnancy outcome. Because the late consequences of in utero antiretroviral exposure for the child are unknown, innovative methods need to be developed to detect possible rare late toxicities of transient perinatal antiretroviral drug exposure that may not be observed until later in childhood or in adolescence or adulthood.

Assessment of Drug Resistance

The risk of emerging drug resistance during pregnancy or the postpartum period requires further study. The

administration of ZDV as a single drug for prophylaxis of transmission may increase the incidence of ZDV resistance mutations in women with viral replication that is not maximally suppressed. Administration of drugs such as nevirapine and 3TC, for which a single-point mutation can confer genotypic resistance, to pregnant women with inadequate viral suppression may result in the development of virus with genotypic drug resistance in a substantial proportion of the women (27,136,137). The clinical consequences of emergence of genotypic resistance during pregnancy or in the postpartum period with respect to risk of transmission of resistant virus and future treatment options require further assessment.

Optimizing Adherence

The complexity of combination antiretroviral regimens as well as drugs for prophylaxis against opportunistic infections often leads to poor adherence among HIV-1-infected persons. Innovative approaches are needed to improve adherence for women with HIV-1 infection during and following pregnancy and to ensure that infants receive ZDV prophylaxis.

Role of Cesarean Delivery Among Women with Nondetectable Viral Load or with Short Duration of Ruptured Membranes

Elective cesarean delivery has increased among women with HIV-1 infection since the demonstration that delivery before labor and membrane rupture can reduce intrapartum HIV-1 transmission (140,141,190). Further study is needed regarding whether elective cesarean delivery provides clinically significant benefit to infected women with low or undetectable viral load who are receiving combination antiretroviral therapy, and also regarding the maternal and infant morbidity and mortality associated with operative delivery. Additionally, data from a meta-analysis by the International Perinatal HIV-1 Group indicate that the risk of perinatal transmission increases by 2% for every 1-hour increase in duration of membrane rupture in infected women with ≤ 24 hours of membrane rupture (191). Therefore, further study is also needed to evaluate the role of nonelective cesarean delivery in reducing perinatal transmission in women with very short duration of ruptured membranes and/or labor.

Management of Women with Premature Rupture of Membranes

With evidence that increasing duration of membrane rupture is associated with an increasing transmission risk (191), more study is needed to determine the appropriate management of pregnant women with HIV-1 infection who present with ruptured membranes at different points in gestation.

Offering Rapid Testing at Delivery to Late-Presenting Women

One of the groups still at high risk for transmitting HIV-1 to their infants is those women who have not received antenatal care and were not offered HIV-1 counseling and testing. The feasibility of offering counseling and rapid HIV-1 testing to women of unknown HIV-1 status who present while in labor requires further study. Additionally, the efficacy and acceptability of intrapartum/postpartum or postpartum infant interventions to reduce the risk of intrapartum transmission by women first identified as infected with HIV-1 during delivery needs to be assessed.

References

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *N Engl J Med* 1994;33:1173-80.
2. CDC. Recommendations of the U.S. Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. *MMWR* 1994;43(RR-11):1-21.
3. CDC. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. *MMWR* 1995;44(RR-7):1-14.
4. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. *J Infect Dis* 1996;174:1207-11.
5. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. *JAMA* 1996;275:1483-8.
6. Fiscus SA, Adimora AA, Funk ML, et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. *Pediatr Infect Dis J* 2002;21:664-8.
7. Thomas P, Singh T, Bornschlegel K, et al. Use of ZDV to prevent perinatal HIV in New York City (NYC) [Abstract 381]. Presented at the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997.
8. Mayaux M-J, Teglas J-P, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. *J Pediatr* 1997;131:857-62.
9. Harris NH, Thompson SJ, Ball R, Hussey J, Sy F. Zidovudine and perinatal human immunodeficiency virus type 1 transmission: a population-based approach. *Pediatrics* 2002;109(4):e60. Available at <http://www.pediatrics.org/cgi/content/full/109/4/e60>.
10. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 1996;271:1582-6.
11. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. *Ann Intern Med* 1996;124:984-94.
12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. *N Engl J Med* 1997;337:725-33.

13. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N Engl J Med* 1997;337:734–9.
14. CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. *MMWR* 1998;47(RR-5):39–82 (Updates available at <http://www.hivatis.org>).
15. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. *Acta Paediatr Suppl* 1997; 421:1–9.
16. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. *J Natl Cancer Inst* 1997;89:1602–8.
17. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. *Am J Obstet Gynecol* 1997;176:478–89.
18. Mills JL. Protecting the embryo from X-rated drugs. *N Engl J Med* 1995;333:124–5.
19. CDC. Pregnancy outcomes following systemic prenatal acyclovir exposure—June 1, 1984–June 30, 1993. *MMWR* 1993;42:806–9.
20. US Department of Health and Human Services, HIV/AIDS Treatment and Information Service. Safety and toxicity of individual antiretroviral agents in pregnancy, May 23, 2002. In: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://www.hivatis.org/guidelines/perinatal/May23_02/STMay23.pdf
21. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. *AIDS* 1998;12:F241–7.
22. The European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. *AIDS* 2000;14:2913–20.
23. Tuomala R. Interim analysis of Pediatric AIDS Clinical Trials Group Protocol 367. Presented at the Pediatric AIDS Clinical Trials Group Meeting, Crystal City, Virginia, July 2000.
24. Martin R, Boyer P, Hammill H, et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. *J Pediatr* 1997;131:851–6.
25. Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992–1994. Pregnancy and HIV Study Group. *AIDS* 1998;12:643–50.
26. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. *Br J Obstet Gynaecol* 1998;105:836–48.
27. Mandelbrot L, Landreau-Mascao A, Rekeciewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal–infant transmission of HIV-1. *JAMA* 2001;285:2083–93.
28. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. *N Engl J Med* 2002;346:1863–70.
29. Food and Drug Administration. FDA Public Health Advisory. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for treatment of human immunodeficiency virus (HIV). Rockville, Md.: US Department of Health and Human Services, Public Health Service, Food and Drug Administration; June 11, 1997.
30. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [letter]. *Ann Intern Med* 1997;127:947.
31. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor [letter]. *Ann Intern Med* 1997;127:948.
32. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies. *AIDS Clinical Care* 1998;10:41–4.
33. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. *AIDS* 1998;12:1735–44.
34. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. *Antimicrob Agents Chemother* 1994;38:2743–9.
35. Boxwell DE, Styrk BA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs) [Abstract 1284]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1999.
36. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. *N Engl J Med* 1999;340:1723–31.
37. Strauss AW, Bennett MJ, Rinaldo P, et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal–maternal interaction cause maternal liver disease and other pregnancy complications. *Semin Perinatol* 1999;23:100–12.
38. Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl Co-A dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. *Proc Natl Acad Sci USA* 1995;92:841–5.
39. Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. *Mol Genet Metab* 2000;71:182–9.
40. Grimbert S, Fromenty B, Fisch C, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. *Hepatology* 1993;17:628–37.
41. Grimbert S, Fisch C, Deschamps D, et al. Effects of female sex hormones on mitochondria: possible role of acute fatty liver of pregnancy. *Am J Physiol* 1995;268(1 Pt 1): G107–15.
42. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. *Am J Gastroenterol* 1995;90:1433–6.
43. Gérard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. *AIDS* 2000;14:2723–30.
44. Luzzati R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavine and severe lactic acidosis. *Lancet* 1999;353:901–2.
45. Bristol-Myers Squibb Company. Healthcare Provider Important Drug Warning Letter. January 5, 2001.
46. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. *Lancet* 1999;354:1084–9.
47. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trials Group 076 Study. *AIDS* 1998;12:1805–13.
48. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. *J Acquir Immune Defic Syndr* 2000;25:261–8.

49. Lange J, Stellato R, Brinkman K, et al. Review of neurological adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: PETRA study [Abstract 250]. Presented at The Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Canada, September 1999.
50. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. *N Engl J Med* 2000;343:759–66.
51. Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? *Lancet* 1999;354:1046–7.
52. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. *N Engl J Med* 1996;335:1621–9.
53. Sandberg JA, Slikker W, Jr. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides. *FASEB J* 1995;9:1157–63.
54. Qian M, Bui T, Ho RJY, Unadkat JD. Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and hofbauer cells. *Biochem Pharmacol* 1994;48:383–9.
55. Dancis J, Lee JD, Mendoza S, Liebes L. Transfer and metabolism of dideoxyinosine by the perfused human placenta. *J Acquir Immune Defic Syndr* 1993;6:2–6.
56. Sandberg JA, Binienda Z, Lipe G, Slikker W, Jr. Placental transfer and fetal disposition of 2',3'-dideoxycytidine and 2',3'-dideoxyinosine in the rhesus monkey. *Drug Metab Dispos* 1995;23:881–4.
57. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International. Interim Report for 1 January 1989 through 31 January 2002. Wilmington, N.C: Registry Coordinating Center, 2002.
58. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. *JAMA* 1999;281:151–7.
59. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. *J Acquir Immune Defic Syndr* 1999;20:463–7.
60. Stiehler ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. *J Infect Dis* 1999;179:567–75.
61. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr* 2002;29:484–94.
62. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. *Lancet* 1999;353:773–80.
63. Lallemand M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. *N Engl J Med* 2000;343:982–91.
64. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomised, double-blind, placebo-controlled trial. *Lancet* 2002;359:1178–86.
65. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *Lancet* 1999;354:795–802.
66. Moodley D. The SAINT Trial: nevirapine (NVP) versus zidovudine (ZDV) + lamivudine (3TC) in prevention of peripartum HIV transmission [Abstract LBO2]. Presented at the XIII International AIDS Conference. Durban, South Africa. July 2001.
67. Lallemand M, Jourdain G, Le Coeur S, et al. Nevirapine (NVP) during labor and in the neonate significantly improves zidovudine (ZDV) prophylaxis for the prevention of perinatal HIV transmission: results of the first interim analysis [Abstract LBO22]. Presented at the XIV International AIDS Conference. Barcelona, Spain. July 2002.
68. Dabis F, Leroy V, Bequet L, et al. Effectiveness of a short course of zidovudine + nevirapine to prevent mother-to-child transmission (PMTCT) of HIV-1: The Ditrane Plus ANRS 1021 Project in Abidjan, Cote d'Ivoire [Abstract ThOr1428]. Presented at the XIV International AIDS Conference. Barcelona, Spain. July 2002.
69. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. *JAMA* 2002;288:189–98.
70. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. *N Engl J Med* 1998;339:1409–14.
71. Wade NA, Birkhead GS, French PT. Short courses of zidovudine and perinatal transmission of HIV. *N Engl J Med* 1999;340:1043.
72. CDC. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood—France, United Kingdom, and United States, January 1988–August 1994. *MMWR* 1995;44:929–33.
73. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. *Nat Med* 1997;3:549–52.
74. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. *JAMA* 1996;275:599–605.
75. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French Perinatal Cohort Studies. *J Infect Dis* 1997;175:172–5.
76. Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. *AIDS* 1997;11:437–44.
77. Shapiro DE, Sperling RS, Coombs RW. Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. *Lancet* 1999;354:156.
78. Mofenson LM, Lambert JS, Stiehler ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. *N Engl J Med* 1999;341:385–93.
79. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. *N Engl J Med* 1999;341:394–402.
80. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. *AIDS* 1999;13:1377–85.

81. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. *AIDS* 1999;13:407–14.
82. Shaffer N, Roongpisuthipong A, Siriwasin W, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. *J Infect Dis* 1999;179:590–9.
83. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. *J Infect Dis* 1999;179:871–82.
84. Iverson AKN, Larsen AR, Jensen T, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. *J Infect Dis* 1998;177:1214–20.
85. Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ. Analysis of HIV-1 in cervicovaginal secretions and blood of pregnant and nonpregnant women. *J Hum Virol* 1999;2:154–66.
86. Rasheed S, Li Z, Xu D, Kovacs A. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. *Am J Obstet Gynecol* 1996;175:122–9.
87. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. *J Infect Dis* 2000;181:99–106.
88. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. *Obstet Gynecol* 1999;94:641–6.
89. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. *J Acquir Immune Defic Syndr* 1997;14:232–6.
90. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. *J Infect Dis* 2001;183:539–45.
91. Tuomala R, Shapiro D, Samelson R, et al. Antepartum antiretroviral therapy and viral load in 464 HIV-infected women in 1998–1999 (PACTG 367) [Abstract 285]. *Am J Obstet Gynecol*, 2000;182:S99.
92. American College of Obstetricians and Gynecologist Technical Bulletin. Preconceptional Care (No. 205). Washington DC: American College of Obstetricians and Gynecologists, May 1995.
93. Burns DN, Landesman S, Muenz LR, et al. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4⁺ levels. *J Acquir Immune Defic Syndr* 1994;7:718–26.
94. Turner BJ, Hauck WW, Fanning TR, Markson LE. Cigarette smoking and maternal-child HIV transmission. *J Acquir Immune Defic Syndr* 1997;14:327–37.
95. Rodriguez EM, Mofenson LM, Chang B-H, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. *AIDS* 1996;10:273–82.
96. Bulterys M, Landesman S, Burns DN, Rubenstein A, Goedert JJ. Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. *J Acquir Immune Defic Syndr* 1997;15:76–82.
97. Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. *AIDS* 1996;10:1249–56.
98. CDC. Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. *MMWR* 1985;34:721–6, 731–2.
99. Rodman JH, Robbins BL, Flynn PM, Fridland A. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. *J Infect Dis* 1996;174:490–9.
100. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. *AIDS* 1996;10:1361–7.
101. Peter K, Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. *Clin Pharmacol Ther* 1996;60:168–76.
102. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. *AIDS* 1994;8:313–21.
103. Mannucci PM, Gringeri A, Savidge G, et al. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. *Br J Haematol* 1994;86:174–9.
104. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4⁺ cell counts greater than 400 per cubic millimeter. *N Engl J Med* 1993;329:297–303.
105. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. *J Pediatr* 1993;122:137–44.
106. Mirochnick M, Capparelli E, Dankner W, Sperling RS, van Dyke R, Spector SA. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. *Antimicrob Agents Chemother* 1998;42:808–12.
107. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. *J Med Virol* 1999;59:364–8.
108. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. *J Infect Dis* 1998;177:557–64.
109. Miotti PG, Taha TET, Kumwenda NI, et al. HIV transmission through breastfeeding. A study in Malawi. *JAMA* 1999;282:744–9.
110. Koup RA, Brewster F, Grob P, Sullivan JL. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. *AIDS* 1993;7:1181–4.
111. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). *AIDS* 1999;13:479–86.
112. Zhang H, Dornadula G, Wu Y, Havlir D, Richman D, Pomerantz R. Kinetic analysis of intraviral reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. *J Virol* 1996;70:628–34.
113. Frenkel LM, Wagner LE, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. *Clin Infect Dis* 1995;20:1321–6.
114. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. *JAMA* 1998;279:1977–83.
115. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. *J Infect Dis* 1999;179:705–8.

116. Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. *AIDS* 1998;12:2281-8.
117. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. *J Infect Dis* 2001;184:1120-6.
118. Van Rompay KK, Otsyula MG, Marthas ML, Miller CJ, McChesney MB, Pedersen NC. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. *Antimicrob Agents Chemother* 1995;39:125-31.
119. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. *Science* 1995;270:1197-9.
120. Böttiger D, Johansson N-G, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIV_{sm}, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. *AIDS* 1997;11:157-62.
121. Mathes LE, Polas PJ, Hayes KA, Swenson CL, Johnson S, Kociba GJ. Pre- and post-exposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine (AZT) inhibits feline leukemia virus disease by a drug-induced vaccine response. *Antimicrob Agents Chemother* 1992;36:2715-21.
122. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. *AIDS* 1995;9:F7-F11.
123. Weinstock H, Respass R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. *J Infect Dis* 2000;182:330-3.
124. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. *JAMA* 1999;282:1142-9.
125. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. *JAMA* 1999;282:1135-41.
126. Pomerantz RJ. Primary HIV-1 resistance: a new phase in the epidemic? *JAMA* 1999;282:1177-9.
127. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study Group. *AIDS* 2000;14:263-71.
128. Sitnitskaya Y, Rochford G, Rigaud M, et al. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995-1999. *Clin Infect Dis* 2001;33:e3-7.
129. Mofenson L, Lambert J, Stiehm ER, et al. Case-control study of perinatal HIV transmission and genotypic and phenotypic markers of reduced susceptibility to zidovudine (ZDV) [Abstract TuPeB4593]. Presented at the XIV International AIDS Conference. Barcelona, Spain, July 2002.
130. Johnson VA, Petropoulos CJ, Woods C, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. *J Infect Dis* 2001;183:1688-93.
131. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beinr Community Programs for Clinical Research on AIDS. *N Engl J Med* 1996;335:1099-106.
132. Bardeguet A, Shapiro D, Mofenson LM, et al. Lack of clinical or immunologic disease progression with transient use of zidovudine to reduce perinatal HIV-1 transmission in Pediatric AIDS Clinical Trials Group Protocol 076. *J Acquir Immune Defic Syndr* 2002 (in press).
133. Clarke SM, Mulcahy F, Healy CM, Condon S, Butler KM. The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome. *Int J STD AIDS* 2000;11:220-3.
134. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. *JAMA* 2000;283:205-11.
135. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. *JAMA* 2000;283:229-34.
136. Eshleman SH, Mrcna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). *AIDS* 2001;15:1951-7.
137. Cunningham CK, Chaix M-L, Rekeciewa C, et al. Development of resistance mutations in women receiving standard retroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. *J Infect Dis* 2002;186:181-8.
138. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. *JAMA* 2000;283:2417-26.
139. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. *AIDS* 2001;15:309-20.
140. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. A meta-analysis of 15 prospective cohort studies. *N Engl J Med* 1999;340:977-87.
141. The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. *Lancet* 1999; 353:1035-9.
142. American College of Obstetricians and Gynecologists Committee Opinion. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234. Washington DC: The American College of Obstetricians and Gynecologists, May 2000.
143. Burns DN, Landesman S, Wright DJ, et al. Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. *J Infect Dis* 1997;175:1206-10.
144. Coll O, Hernandez M, Boucher CAB, et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. *J Acquir Immune Defic Syndr* 1997;14:26-30.
145. Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. *J Infect Dis* 1999;179:319-28.
146. Samelson R, Shapiro D, Tuomala, et al. HIV vertical transmission rates according to antiretroviral therapy and viral load during pregnancy among 347 mother-child pairs 1998-99 (PACTG 367) [Abstract 276]. Presented at the Society for Maternal Fetal Medicine Annual Meeting. Miami Beach, Florida, January 2000.

147. Blattner W, Cooper E, Charurat M, et al. Effectiveness of potent antiretroviral therapies on reducing perinatal transmission of HIV-1 [Abstract LbOr4]. Presented at the XIII International AIDS Conference. Durban, South Africa, July 2000.
148. Beckerman KP, Morris AB, Stek A. Mode of delivery and the risk of vertical transmission of HIV-1. [Letter]. *N Engl J Med* 1999;341:205–6.
149. Helfgott AW, Eriksen N, Lewis S, Doyle M, Pearson D, Bundrick C. Highly active antiretroviral therapy for the prevention of perinatal HIV [Abstract 289]. Presented at the Society for Maternal Fetal Medicine Annual Meeting. Miami Beach, Florida, January 2000.
150. Nielsen TF, Hökegard K-H. Postoperative cesarean section morbidity: a prospective study. *Am J Obstet Gynecol* 1983;146:911–5.
151. Hebert PR, Reed G, Entman SS, Mitchel EF, Berg C, Griffin MR. Serious maternal morbidity after childbirth: prolonged hospital stays and readmissions. *Obstet Gynecol* 1999;94:942–7.
152. Roman J, Bakos O, Cnattingius S. Pregnancy outcomes by mode of delivery among term breech births: Swedish experience 1987–1993. *Obstet Gynecol* 1998;92:945–50.
153. Gregory KD, Henry OA, Ramicone E, Chan LS, Platt LD. Maternal and infant complications in high and normal weight infants by method of delivery. *Obstet Gynecol*, 1998;92:507–13.
154. Schiff E, Friedman SA, Mashich S, Hart O, Barkal G, Sibai BM. Maternal and neonatal outcome of 846 term singleton breech deliveries: seven-year experience at a single center. *Am J Obstet Gynecol* 1996;175:18–23.
155. van Ham MA, van Dongen PWJ, Mulder J. Maternal consequences of caesarean section. A retrospective study of intra-operative and post-operative maternal complications of caesarean section during a 10-year period. *Eur J Obstet Gynecol Reprod Biol* 1997;74:1–6.
156. McMahon MJ, Luther ER, Bowes WA Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section. *N Engl J Med*, 1996;335:689–95.
157. Watts DH, Lambert JS, Stiehm ER, et al. Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of $\leq 500/\mu\text{L}$. *Am J Obstet Gynecol* 2000;183:100–7.
158. Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study. *J Acquir Immune Defic Syndr* 2001;26:236–45.
159. Marcollet A, Goffinet F, Firtion G, et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. *Am J Obstet Gynecol* 2002;186:784–9.
160. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after caesarean section in 156 HIV-positive women. *AIDS* 1995;9:913–17.
161. Grubert TA, Reindell D, Kastner R, Lutz-Friedrich R, Belohradsky BH, Dathe O. Complications after caesarean section in HIV-1-infected women not taking antiretroviral treatment. *Lancet* 1999; 354:1612–3.
162. Maiques-Montesinos V, Cervera-Sanchez J, Bellver-Pradas J, Abad-Carrascosa A, Serra-Serra V. Post-cesarean section morbidity in HIV-positive women. *Acta Obstet Gynecol Scand* 1999; 78:789–92.
163. Vimercati A, Greco P, Loverro G, Lopalco PL, Pansini V, Selvaggi L. Maternal complications after caesarean section in HIV infected women. *Eur J Obstet Gynecol Reprod Biol* 2000;90:73–6.
164. Grubert TA, Reindell D, Kastner R, et al. Rates of postoperative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures. *Clin Infect Dis* 2002;34:822–30.
165. Rodriguez EJ, Spann C, Jamieson D, Lindsay M. Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. *Am J Obstet Gynecol* 2001;184:1108–11.
166. Urbani G, de Vries MMJ, Cronje HS, Niemand I, Bam RH, Beyer E. Complications associated with cesarean section in HIV-infected patients. *Int J Gynaecol Obstet* 2001;74:9–15.
167. American College of Obstetricians and Gynecologists Educational Bulletin. Assessment of fetal lung maturity. Number 230. Washington DC: American College of Obstetricians and Gynecologists, November 1996. *Int J Gynaecol Obstet* 1996;56:191–8.
168. Parilla BV, Dooley SL, Jansen RD, Socol ML. Iatrogenic respiratory distress syndrome following elective repeat cesarean delivery. *Obstet Gynecol* 1993;81:392–5.
169. Madar J, Richmond S, Hey E. Surfactant-deficient respiratory distress after elective delivery at “term.” *Acta Paediatr* 1999;88:1244–8.
170. American College of Obstetricians and Gynecologists Educational Bulletin. Antimicrobial therapy for obstetric patients. Number 245. Washington DC: American College of Obstetricians and Gynecologists, March 1998. *Int J Gynaecol Obstet* 1988;61:299–30.
171. Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. *Am J Obstet Gynecol* 1995;173:585–9.
172. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. *N Engl J Med* 1996;334:1617–23.
173. Mandelbrot L, Mayaux M-J, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: The French Perinatal Cohorts. SEROGEST French Pediatric HIV Infection Study Group. *Am J Obstet Gynecol* 1996;175:661–7.
174. Shapiro DE, Sperling RS, Mandelbrot L, Britto P, Cunningham BE. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Pediatric AIDS Clinical Trials Group protocol 076 Study Group. *Obstet Gynecol* 1999;94:897–908.
175. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. *JAMA* 1994;271:1925–30.
176. Kind C, Rudin C, Siegrist C-A et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. *AIDS* 1998;12:205–10.
177. Miotti PG, Liomba G, Dallabetta GA, Hoover DR, Chiphangwi JD, Saah AJ. T-lymphocyte subsets during and after pregnancy: analysis in human immunodeficiency virus type 1-infected and -uninfected Malawian mothers. *J Infect Dis* 1992;165:1116–9.
178. Tuomala RE, Kalish LA, Zorilla C, et al. Changes in total, CD4⁺, and CD8⁺ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. *Obstet Gynecol* 1997;89:967–74.
179. CDC. 1995 revised guidelines for prophylaxis against *Pneumocystis carinii* pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. *MMWR* 1995;44(RR-4):1–11.

180. American Academy of Pediatrics, Committee on Pediatric AIDS. Evaluation and medical treatment of the HIV-exposed infant. *Pediatrics* 1997;99:909–17.
181. Kovacs A, Xu J, Rasheed S, et al. Comparison of a rapid nonisotopic polymerase chain reaction assay with four commonly used methods for the early diagnosis of human immunodeficiency virus type 1 infection in neonates and children. *Pediatr Infect Dis J* 1995;14:948–54.
182. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. *Br J Psychiatry* 1987;150:662–73.
183. Ickovics JR, Wilson TE, Royce RA et al. Prenatal and postnatal zidovudine adherence among pregnant women with HIV. *J Acquir Immune Defic Syndr* 2002;30:21–30.
184. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000;133:21–30.
185. Richter A, Simpson KN, Manskopf JA. Impact of drug non-compliance and the frequency of viral load testing on outcomes, costs and patterns of therapy [Abstract 42173]. Presented at the 12th World AIDS Conference. Geneva, Switzerland, June–July 1998.
186. Le Moing V, Masquelier B, Moatti JP, et al. To study predictors of immunologic response (IR) to PI therapy, along with virologic response (VR), including adherence to therapy [Abstract 596]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1999.
187. Murri R, Ammasari A, Gallicano K, et al. Relationship of self-reported adherence to HAART with protease inhibitor (PI) plasma level and viral load (VL) [Abstract 593]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1999.
188. Miller L, Lui H, Beck K, et al. Providers' estimates of adherence overestimate reports from medication event monitoring (MEMS) for patients on protease inhibitors [Abstract 97]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January–February 1999.
189. Melbourne KM, Geletko SM, Brown SL, Willey-Lessne C, Chase S, Fisher A. Medication adherence in patients with HIV infection: a comparison of two measurement methods. *The AIDS Reader* 1999;9:329–38.
190. Dominguez K, Lindegren M, Fowler M, et al. Increasing trends in cesarean sections in HIV-infected mothers of infants in the Pediatric Spectrum of HIV Disease (PSD) cohort [Abstract 702]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
191. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. *AIDS* 2001;15:357–68.



MMWRTM

Morbidity and Mortality Weekly Report

Recommendations and Reports

November 22, 2002 / Vol. 51 / No. RR-18

Continuing Education Activity Sponsored by CDC U.S. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States

EXPIRATION — November 22, 2005

You must complete and return the response form electronically or by mail by **November 22, 2005**, to receive continuing education credit. If you answer all of the questions, you will receive an award letter for 2.5 hours Continuing Medical Education (CME) credit; 0.25 Continuing Education

Units (CEUs); or 3.0 contact hours Continuing Nursing Education (CNE) credit. If you return the form electronically, you will receive educational credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees are charged for participating in this continuing education activity.

INSTRUCTIONS

By Internet

1. Read this *MMWR* (Vol. 51, RR-18), which contains the correct answers to the questions beginning on the next page.
2. Go to the *MMWR* Continuing Education Internet site at <http://www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
6. Submit your answers no later than **November 22, 2005**.
7. Immediately print your Certificate of Completion for your records.

By Mail or Fax

1. Read this *MMWR* (Vol. 50, RR-18), which contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
5. Sign and date the response form or a photocopy of the form and send no later than **November 22, 2005**, to
Fax: 404-639-4198 Mail: MMWR CE Credit
Office of Scientific and Health Communications
Epidemiology Program Office, MS C-08
Centers for Disease Control and Prevention
1600 Clifton Rd, N.E.
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.

ACCREDITATION

Continuing Medical Education (CME). CDC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CDC designates this educational activity for a maximum of 2.5 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Continuing Education Unit (CEU). CDC has been approved as an authorized provider of continuing education and training programs by the International Association for Continuing Education and Training and awards 0.25 Continuing Education Units (CEUs).

Continuing Nursing Education (CNE). This activity for 3.0 contact hours is provided by CDC, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

CENTERS FOR DISEASE CONTROL AND PREVENTION

SAFER • HEALTHIER • PEOPLETM

Goal and Objectives

This *MMWR* provides recommendations regarding the treatment of pregnant women in the United States with human immunodeficiency virus type 1 (HIV-1) infection for both maternal health and the prevention of perinatal HIV-1 transmission. These recommendations were prepared by the U.S. Public Health Service Perinatal HIV Guidelines Working Group, which consists of public health, obstetric, and pediatric specialists and women infected with HIV-1. The goal of this report is to provide evidence-based guidance to public- and private-sector policy makers and clinical providers on antiretroviral treatment and obstetric management during pregnancy. Upon completion of this continuing education activity, the reader should be able to 1) describe the recommended antiretroviral regimens for women presenting to the health-care provider with a variety of clinical histories, 2) identify potential toxicities, 3) describe obstetric interventions to help reduce perinatal HIV-1 transmission, and 4) describe the information that pregnant women should receive when making decisions about antiretroviral therapy during pregnancy.

To receive continuing education credit, please answer all of the following questions.

1. **All of the following statements regarding perinatal HIV-1 transmission and mode of delivery are true except:**
 - A. The recommended gestational age to perform an elective (scheduled) cesarean delivery for prevention of mother-to-child HIV-1 transmission is 38 weeks' gestation.
 - B. The risk of perinatal HIV-1 transmission has been shown to be reduced by scheduled cesarean section before labor for women with viral loads <1,000 copies/mL.
 - C. When scheduled cesarean delivery is to be performed, the intravenous infusion of zidovudine (ZDV) prophylaxis should be initiated 3 hours before surgery.
 - D. Women should make their own decisions regarding mode of delivery after discussing the known potential risks and benefits with their provider.
2. **An initial clinical assessment of an HIV-1-infected pregnant woman should include. . .**
 - A. an evaluation of the degree of existing immunodeficiency determined by CD4⁺ count.
 - B. history of prior or current antiretroviral therapy.
 - C. gestational age.
 - D. risk for disease progression as determined by the level of plasma HIV-1 RNA.
 - E. supportive care needs.
 - F. all of the above.
3. **Which of the following statements represent known complications of antiretroviral therapy in HIV-1-infected women?**
 - A. Combination antiretroviral therapy during pregnancy is associated with adverse pregnancy outcome, including preterm delivery and low birth weight.
 - B. Hyperglycemia has been observed with protease inhibitor treatment.
 - C. Severe lactic acidosis in late pregnancy has been observed in HIV-1-infected women who received d4T-ddI (stavudine-didanosine) as part of a combination antiretroviral regimen during pregnancy.
 - D. B and C only.
 - E. All of the above.
4. **The mechanism(s) by which antiretroviral prophylaxis reduces mother-to-child- transmission is. . .**
 - A. reducing maternal antenatal plasma HIV-1 viral load.
 - B. transplacental passage of antiretroviral agents to the fetus before passage through the birth canal, providing preexposure prophylaxis of the fetus.
 - C. provision of antiretroviral drugs to the infant after birth, providing postexposure prophylaxis of the infant against virus or infected cells that may have entered the infant's circulation during delivery.
 - D. all of the above.
5. **When prescribing antiretroviral therapy for a pregnant woman, a clinician should. . .**
 - A. aim to decrease antenatal plasma HIV-1 viral load to undetectable or <1000 copies/ml.
 - B. consider the short- and long-term effects of the antiretroviral drugs on the pregnant woman and on the fetus/infant.
 - C. consider potential changes in antiretroviral drug dosing requirements caused by pregnancy.
 - D. discuss with the woman her ability to adhere to the considered regimen.
 - E. all of the above.
6. **Antiretroviral drugs that should be avoided in antiretroviral drug regimens for HIV-1-infected pregnant women or for HIV-1-infected women intending to become pregnant are. . .**
 - A. ZDV.
 - B. d4T-ddI.
 - C. efavirenz.
 - D. nevirapine.
 - E. all of the above.
 - F. B and C only.
7. **If a woman in labor and delivery has no history of prenatal care and has a rapid HIV-1 test or an expedited enzyme-link immunoassay (EIA) that is positive for HIV-1 antibody, which course of antiretroviral therapy should be administered?**
 - A. None. Antiretroviral therapy should be administered only after obtaining a confirmatory EIA and Western blot.
 - B. A single dose of nevirapine to the woman as soon as possible, followed by a single dose of nevirapine to the newborn at age 48 hours.
 - C. Oral ZDV and 3TC during labor, followed by 1 week of oral ZDV-3TC for the newborn.
 - D. The single-dose maternal/infant nevirapine regimen (choice B) plus intravenous ZDV during labor and delivery and 6 weeks of ZDV for the newborn.
 - E. Intravenous ZDV during labor and delivery and 6 weeks of ZDV for the newborn.
 - F. Any of the above except A.
8. **Why should dual nucleoside therapy not be the first choice of treatment regimens for pregnant women infected with HIV-1?**
 - A. Poor acceptability among pregnant women.
 - B. Dual nucleoside therapy has been shown increase fetal mortality.
 - C. Concerns exist regarding the potential for inadequate viral suppression and rapid development of resistance.
 - D. Dual nucleoside therapy is ineffective in preventing perinatal HIV-1 transmission.
9. **In clinical trials, single-dose nevirapine to the mother in labor and to the infant 2 days after birth has been demonstrated to dramatically reduce perinatal HIV-1 transmission. Given these findings, single-dose maternal/infant nevirapine should be added to the intrapartum regimen of women already receiving prenatal antiretroviral therapy.**
 - A. True.
 - B. False.
10. **If a woman has received antiretroviral therapy during pregnancy and has undergone a scheduled elective cesarean delivery for prevention of perinatal HIV-1 transmission, administration of ZDV to the infant for 6 weeks is not necessary.**
 - A. True.
 - B. False.

11. The recommendation for prevention of mother-to-child HIV-1 transmission in infants born to HIV-1-infected women who have not received antiretroviral therapy during pregnancy or labor is. . .
- A. ZDV, starting at age 72 hours and continued for 6 weeks.
 - B. single dose of ZDV at birth.
 - C. immediate HIV-1 DNA PCR to determine HIV-1 infection status, with initiation of ZDV prophylaxis for 6 weeks if the test result is negative.
 - D. ZDV, starting within 6–12 hours of birth and continued for 6 weeks.
12. Follow-up of HIV-1–uninfected children with in utero exposure to antiretroviral prophylaxis. . .
- A. is unnecessary once an infant is determined to be uninfected.
 - B. should continue through age 18 months.
 - C. should continue until age 5 years.
 - D. should continue long term to adulthood.

13. Indicate your work setting.
- A. State/local health department.
 - B. Other public health setting.
 - C. Hospital clinic/private practice.
 - D. Managed care organization.
 - E. Academic institution.
 - F. Other.

14. Which best describes your professional activities?
- A. Laboratory/pharmacy.
 - B. Counseling.
 - C. Administration.
 - D. Patient care—private medical setting.
 - E. Client care—publicly funded site.
 - F. Public health.

15. I plan to use these recommendations as the basis for. . . (Indicate all that apply.)
- A. health education materials.
 - B. insurance reimbursement policies.
 - C. local practice guidelines.
 - D. public policy.
 - E. other.

16. Each month, approximately how many HIV+ women of childbearing age do you see?
- A. None.
 - B. 1–5.
 - C. 6–20.
 - D. 21–50.
 - E. 51–100.
 - F. >100.

17. How much time did you spend reading this report and completing the exam?
- A. Less than 1.5 hours.
 - B. More than 1.5 hours but fewer than 2 hours.
 - C. 2–2.5 hours.
 - D. More than 2.5 hours but fewer than 3 hours.
 - E. 3 hours or more.

18. After reading this report, I am confident I can describe the recommendations for antiretroviral therapy of HIV-1-infected women and their infants to help reduce perinatal HIV-1 transmission in a variety of different situations (no prior therapy; currently receiving therapy; no antenatal therapy; no antenatal or intrapartum therapy).
- A. Strongly agree.
 - B. Agree.
 - C. Neither agree nor disagree.
 - D. Disagree.
 - E. Strongly disagree.

Detach or photocopy.

**MMWR Response Form for Continuing Education Credit
November 22, 2002/Vol. 51/No. RR-18
U.S. Public Health Service Task Force Recommendations for Use of
Antiretroviral Drugs in Pregnant HIV-1-Infected Women for
Maternal Health and Interventions To Reduce Perinatal HIV-1
Transmission in the United States**

To receive continuing education credit, you must
1. provide your contact information;
2. indicate your choice of CME, CEU, or CNE credit;
3. answer all of the test questions;
4. sign and date this form or a photocopy;
5. submit your answer form by XXXX XX, 2005.
Failure to complete these items can result in a delay or rejection of your application for continuing education credit.

Check One
 CME Credit
 CEU Credit
 CNE Credit

Last Name _____ First Name _____
 Street Address or P.O. Box _____
 Apartment _____ or _____ Suite _____
 City _____ State _____ ZIP Code _____
 Phone Number _____ Fax Number _____
 E-Mail Address _____

Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to receive continuing education credit!

1. [] A [] B [] C [] D [] E [] F	15. [] A [] B [] C [] D [] E [] F
2. [] A [] B [] C [] D [] E [] F	16. [] A [] B [] C [] D [] E [] F
3. [] A [] B [] C [] D [] E [] F	17. [] A [] B [] C [] D [] E [] F
4. [] A [] B [] C [] D [] E [] F	18. [] A [] B [] C [] D [] E [] F
5. [] A [] B [] C [] D [] E [] F	19. [] A [] B [] C [] D [] E [] F
6. [] A [] B [] C [] D [] E [] F	20. [] A [] B [] C [] D [] E [] F
7. [] A [] B [] C [] D [] E [] F	21. [] A [] B [] C [] D [] E [] F
8. [] A [] B [] C [] D [] E [] F	22. [] A [] B [] C [] D [] E [] F
9. [] A [] B [] C [] D [] E [] F	23. [] A [] B [] C [] D [] E [] F
10. [] A [] B [] C [] D [] E [] F	24. [] A [] B [] C [] D [] E [] F
11. [] A [] B [] C [] D [] E [] F	25. [] A [] B [] C [] D [] E [] F
12. [] A [] B [] C [] D [] E [] F	26. [] A [] B [] C [] D [] E [] F
13. [] A [] B [] C [] D [] E [] F	27. [] A [] B [] C [] D [] E [] F
14. [] A [] B [] C [] D [] E [] F	

Signature _____ Date I Completed Exam _____

19. After reading this report, I am confident I can identify potential toxicities of antiretroviral drugs in pregnant women and their infants.
- A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
20. After reading this report, I am confident I can describe when scheduled cesarean delivery is recommended for HIV-infected pregnant women to help reduce perinatal HIV transmission.
- A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
21. After reading this report, I am confident I can describe the information that should be provided to pregnant HIV-infected women to assist them in making decisions about choice of antiretroviral therapy during pregnancy.
- A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
22. Overall, the objectives are relevant to the goal of this report.
- A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree or disagree.
23. The tables and text boxes are useful.
- A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
24. Overall, the presentation of the report enhanced my ability to understand the material.
- A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. These recommendations will affect my practice.
- A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. The availability of continuing education credit influenced my decision to read this report.
- A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
27. How did you learn about this continuing education activity?
- A. Internet
B. Advertisement (e.g., fact sheet, *MMWR* cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. *MMWR* subscription.
F. Other.

Correct answers for questions 1-12.
1. B; 2. F; 3. D; 4. D; 5. E; 6. F; 7. F; 8. C; 9. B; 10. B; 11. D; 12. D

Perinatal HIV Guidelines Working Group Members

August 28, 2002

Executive Secretary: Lynne Mofenson, M.D., National Institutes of Health, Rockville, Maryland.

Consultants: Jean Anderson, M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland; Claire Rappoport, Brisbane, California; I. Celine Hanson, M.D., Texas Department of Health, Austin, Texas; Robert Maupin, M.D., Louisiana State University Health Sciences Center, New Orleans, Louisiana; Howard Minkoff, M.D., Maimonides Medical Center, Brooklyn, New York; Mary Jo O'Sullivan, M.D., University of Miami School of Medicine, Miami, Florida; Sallie Marie Perryman New York State Department of Health AIDS Institute, New York, New York; Gwendolyn Scott, M.D., University of Miami School of Medicine, Miami, Florida; Stephen Spector, M.D., University of California San Diego, La Jolla, California; Ruth Tuomala, M.D., Brigham and Women's Hospital, Boston, Massachusetts; Nancy Wade, M.D., The Childrens Hospital at Albany Medical Center, Albany, New York; Patricia Whitley-Williams, M.D., University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey; Catherine Wilfert, M.D., Elizabeth Glaser Pediatric AIDS Foundation, Chapel Hill, North Carolina; Carmen Zorrilla, M.D., University of Puerto Rico School of Medicine, San Juan, Puerto Rico.

Federal Government Staff: Magda Barini-Garcia, M.D., Health Resources and Services Administration, Rockville, Maryland; Melisse Baylor, M.D., Food and Drug Administration, Rockville, Maryland; Mary Glenn Fowler, M.D., Centers for Disease Control and Prevention, Atlanta, Georgia; Victoria Cargill M.D., Office of HIV/AIDS Policy, Washington, D.C.; Karen Hench, Health Resources and Services Administration, Rockville, Maryland; Denise Jamieson, M.D., Centers for Disease Control and Prevention, Atlanta, Georgia; James McNamara, M.D., National Institutes of Health, Rockville, Maryland; Jose Morales, M.D., Health Resources and Services Administration, Rockville, Maryland; D. Heather Watts, M.D., National Institutes of Health, Rockville, Maryland.

Working Group Coordinating Center Staff: Carolyn Burr, Ed.D., National Pediatric and Family HIV Resource Center, Newark, New Jersey; Elaine Gross, M.S., National Pediatric and Family HIV Resource Center, Newark, New Jersey.

All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

The *Morbidity and Mortality Weekly Report (MMWR)* series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's Internet server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.

All material in the *MMWR* series is in the public domain and may be used and reprinted without permission; however, citation of the source is appreciated.